Nifty Pharma

Alkem Laboratories: Board Approves Bigger Investment For New Greenfield Formulations Plant In Ujjain, Rises To ₹1,036 Crores From ₹533 Crores, To Be Done In Phases.

Lupin: Completes Visufarma B.V. Acquisition, Expanding Its Eye Care Portfolio To 60+ Branded Products And Strengthening Its Europe Presence.

Lupin: Unit Nanomi Plans To Buy Up To 43.38% Of Multicare Pharmaceuticals Philippines For as Much as USD 39.6 Million, With Goal Of Taking Full Ownership By May 2026

Glenmark Pharmaceuticals: Company Starts Direct U.S. Sales Of Ryaltris, Growing Its Innovative Product Line

Sun Pharmaceutical Industries Ltd.: Rs. 17.80 Crores NSE Block Trade; for ~ 101,082 Shares, at Rs. 1761.30

LUPIN LTD.: RS. 236.53 CRORES NSE BLOCK TRADE; FOR ~ 1,031,642 SHARES, AT RS. 2292.80

Lupin: Co. Receives Tentative Approval from U.S. FDA for Sugammadex Injection

Lupin: co Gets Tentative U.S. FDA Approval For Sugammadex Injection

Alkem Labs: Company Incorporates A Fully Owned Subsidiary In Dubai Healthcare City, UAE

Aurobindo Pharma: Will Finish Buying 26% Of Swarnaakshu Solar By June 30 After State Government Approval For Its Captive Solar Plant

Sun Pharma: HC Bars Intas From Selling Cancer Drug Similar To Sun Pharma’s “Bevetyx”

Lupin: Subsidiary Multicare Pharmaceuticals Philippines Buys Back 2,813,811 Shares, Boosting Nanomi’s Stake In MPPI From 51% To 56.28%.

Wockhardt: Zaynich Gets Positive CDSCO Expert Panel Nod For Gram-Negative Infection Treatment Ahead Of DCGI Approval

Wockhardt: Zaynich Gets Positive CDSCO Expert Panel Nod For Gram-Negative Infection Treatment Ahead Of DCGI Approval

Sun Pharma: Partner Philogen Reports Mixed Trial Results, Misses Some Phase II Targets While Advancing Glio Programs And Planning Phase III Fibrosarc-2, Plus US And EU Progress For NIDLEGY

Sun Pharma: Company Highlights Progress In Alopecia Areata, Psoriasis, And Acne Research At 2026 AAD Annual Meeting

Sun Pharmaceutical Industries Ltd.: Rs. 25.04 Crores NSE Block Trade; for ~ 139,124 Shares, at Rs. 1800.00

Mankind Pharma: Morgan Stanley on Mankind Pharma Overweight (Initiated), Target Price Rs 2500 as 11% revenue CAGR, ~25% EPS CAGR, domestic recovery, Bharat Serums and Vaccines optionality and 11–12% IPM growth drive superior risk-reward.

Torrent Pharma: Morgan Stanley on Torrent Pharmaceuticals Equal Weight (Initiated), Target Price Rs 4580 as strong chronic-led IPM presence (~5% share) and ₹3–4.5bn cost synergies post integration support medium-term growth, but FY27 seen as transition year with limited upside after recent re-rating.

Lupin: Gets Tentative U.S. FDA Approval For Pitolisant Tablets 4.45mg And 17.8mg

Dr Reddy’s Lab: Delhi High Court Orders Co To Stop Selling Olympiq, NDTV Profit Reports - ndtv profit

IPCA LABORATORIES LTD.: RS. 60.65 CRORES NSE BLOCK TRADE; FOR ~ 381,656 SHARES, AT RS. 1589.00

Lupin: U.S. FDA Gives Tentative Approval To Pitolisant Tablets

Sun Pharmaceutical Industries: UBS on Sun Pharmaceutical Industries Buy, Target Price Rs 2200 (cut from 2450) as rising specialty mix led by Illumya, Leqselvi and Unloxcyt supports growth and margins, with additional upside from potential Semaglutide launch in India.

Aurobindo Pharma: UBS on Aurobindo Pharma Neutral, Target Price Rs 1400 (raised from 1200) as risk-reward remains balanced with moderated US base, gradual diversification (Eugia III inspected) and meaningful contribution expected only from FY28-29.

Cipla: UBS on Cipla Neutral, Target Price Rs 1400 (cut from 1750) as strong pipeline supports medium-term growth, but near-term supply headwinds including Lanreotide issues limit catalysts and weigh on outlook.

Dr. Reddys Lab: Co to Consider Q4 Results on May 12

Divis Lab: Receives Draft Tax Assessment Order Suggesting ₹570.51 Crore Additions For FY23; Plans To Challenge Transfer Pricing And Corporate Tax Adjustments

Torrent Pharma: Launches Oral And Injectable Semaglutide, First In India To Offer Generic Oral Formulation; Injectable Priced At RS. 3,999 Monthly

Alkem Lab: Launches Semaglutide Injection In India With Weekly Treatment Cost Of INR 450

DR. REDDY’S LABORATORIES: CO ANNOUNCES LAUNCH OF INDIA’S FIRST DCGI-APPROVED SEMAGLUTIDE INJECTION ‘OBEDA®’ FOR TYPE 2 DIABETES.

SUN PHARMA: CO LAUNCHES ITS SEMAGLUTIDE INJECTION UNDER THE BRAND NAMES, NOVELTREAT AND SEMATRINITY IN INDIA.

ZYDUS LIFESCIENCES: CO LAUNCHES SEMAGLUTIDE INJECTION IN AN INNOVATIVE, REUSABLE MULTI-DOSE PEN DEVICE IN INDIA.

GLENMARK PHARMACEUTICALS: CO LAUNCHES GLIPIQ® (SEMAGLUTIDE) IN INDIA -- SETTING A NEW BENCHMARK IN AFFORDABILITY FOR GLP-1 THERAPY, WITH WEEKLY TREATMENT STARTING AT ₹325.

Alkem Laboratories: Gets GMP Compliance Certificate From Malta Medicines Authority For Daman Facility, Valid For 3 Years Starting December 9, 2025.

Aurobindo Pharma: Cos Unit-V of Apitoria Pharma Labeled as VAI by USFDA; Inspection Held from December 1 to 12, 2025; Form 483 Issued with Three Observations.

Laurus Labs: MOSL on Laurus Labs: Buy, TP Rs 1280 as deepening CDMO relationships, dedicated capacity expansion, strategic JV with KRKA for EU/APAC formulations, and volume-driven ARV growth with stable pricing support strong medium-term outlook.

Cipla: Approves Investment Up To $100 Million In Equity Shares Of Cipla (EU) Limited And Agrees To Merge Inzpera Health Sciences Limited With The Company.

Zydus Lifesciences: Launches Aerolife Mini™, A New Foldable Inhaler For Asthma And COPD Patients Aimed At Enhancing Drug Delivery And Patient Adherence.

Glenmark Pharma: Glenmark Pharmaceuticals Inc. Launches Milnacipran Hydrochloride Tablets, A Generic Version Of Savella, In The U.S. Market Worth $103 Million

Glenmark Pharma: Gets US FDA Approval For Fluticasone Nasal Spray Aiming At $384 Million OTC Market.

Lupin: Company Announces Expansion of Manufacturing Facility in Dabhasa, India, Boosting Development and Manufacturing Strengths.

Alkem Lab: Company Acquires 30 Acres Of Land From DMIC Vikram Udyogpuri Limited In Ujjain, Board Greenlights ₹533 Crore Investment For New Formulations Factory

Zydus Lifesciences: Partners With Torrent Pharma For Co-Marketing Semaglutide Injection In India; Zydus Will Market It As Semaglyn, Mashemat, And Alterme While Torrent Calls It Sembolic; Efforts Aim To Enhance Patient Access For Type 2 Diabetes And Weight Control.

Lupin Ltd.: Rs. 32.74 Crores NSE Block Trade; for ~ 142,339 Shares, at Rs. 2300.20

Mankind Pharma: Purchases Rivotril Brand in India To Boost CNS Treatments; Gains Exclusive Rights For Production, Sales, And Distribution; Enhances Options For Neurological Care.

Aurobindo Pharmas: US FDA Delivers Form 483 With 9 Observations; Eugia Pharma Unit-II, Designating It As Official Action Indicated.

CIPLA LTD.: RS. 57.04 CRORES NSE BLOCK TRADE; FOR ~ 442,266 SHARES, AT RS. 1289.80

Lupin: Enters Licensing Deal With Zydus Lifesciences To Co-Brand Semaglutide Injection In India; Zydus Will Market As Semaglyntm, Mashematm, Altermetm, While Lupin Will Use The Names Semanext® And Livarise®.

Zydus Lifesciences: Enters Agreement With Lupin To Co-Market Semaglutide Injection In India, Zydus Will Promote It As Semaglyntm, Mashematm, And Altermetm, While Lupin Will Sell It As Semanext And Livarise.

Zydus Lifesciences: SentyNL Therapeutics Signs Deal With PRG S&T To License Molecule For Hutchinson-Gilford Progeria Syndrome

Sun Pharma: SBLA Application For Ilumya® To Treat Adults With Active Psoriatic Arthritis Approved By US FDA

Glenmark Pharma: Glenmark Pharmaceuticals Inc., USA Is Set To Release Potassium Phosphates Injection In The US, With Annual Sales Nearing USD 50.7 Million.

Zydus Lifesciences: co Licenses Drug Desidustat To China Medical System Holdings After Approval From Chinas NMPA.

Dr. Reddys: Receives Advice to Stop TACTI-004 Phase III Trial After Interim Analysis Shows No Progress, ImmuneP Also To Stop Enrollment and Close TACTI-004 Phase III Study

Zydus Lifesciences: Co Gets Final USFDA Approval For Cevimeline Hydrochloride Capsules 30mg For Treating Dry Mouth Linked To Sjögren’s Syndrome; Expected Annual Sales Are USD 26.9 Million.

Laurus Lab: Sees 47% Decrease In Export Revenue To $36 Million In February 2026.

Biocon: Company’s Arm Receives FDA Approval For Liraglutide Injection (Gvictoza®) To Treat Type 2 Diabetes, Boosting Its Complex Drug Offerings

Aurobindo Pharma: APL Healthcares Unit-IV Receives VAI Classification From US FDA Following Inspection Conducted From December 8 To December 17, 2025; Five Issues Were Noted, And The Inspection Is Now Concluded.

Cipla: Morgan Stanley maintains Underweight on Cipla with Target Price Rs 1,211, citing Lanreotide injection batch recalls from Pharmathen’s Radopi facility, likely delaying US resupply, risking market share loss, and potential downside to FY27–FY28 earnings.

Glenmark Pharmaceuticals: HSBC maintains Buy on Glenmark Pharmaceuticals with Target Price Rs 2,600 (raised), citing USFDA approval of gFlovent 44mcg inhaler improving US sales trajectory, with learnings aiding gFlovent 110mcg ANDA review, and consistent new US approvals seen as the key catalyst.

Dr. Reddys: Delhi High Court Grants Permission For Dr. Reddys To Manufacture And Export Semaglutide Despite Patent Dispute With Novo Nordisk.

Divis Laboratories: Jefferies maintains Buy on Divis Laboratories with target price ₹8,200, citing its scaling as a GLP and peptide CDMO, potential $600m (oral GLP) + $400m+ (injectable GLP) revenue by FY32, strong peptide pipeline and Big Pharma ties including benefits from Eli Lilly’s India supply-chain push, driving ~15% revenue and ~20% EPS growth over FY26–32E.

Cipla: Cipla USA Starts Recall of Lanreotide Injection Batches, Leading to Short-Term Supply Issues.

Biocon: FDA Reduces Rules For Drug Companies Making Cheaper Versions Of Expensive Biologic Drugs.

Dr Reddys: Delhi High Court Approves Dr Reddys Export Of Semaglutide To Certain Countries.

Lupin: Higher Oil Prices May Cause Increase in Solvent Costs

Lupin: Company Reports Cargo Movement Affected Due To Container Delays At Ports From Europe And The Middle East.-Cnbc TV18

Torrent Pharmaceuticals: Citi maintains Buy on Torrent Pharmaceuticals with Target Price Rs 5,100, citing JB acquisition integration with ₹400–450 cr cost synergies, revenue synergies and stronger IPM/emerging markets scale driving double-digit India growth, US business targeting $200m+ scale, steady EBITDA margin expansion, and net debt turning to net cash by FY30 despite a possibly soft Q4FY26.

Lupin: Morgan Stanley maintains Equal-Weight on Lupin Limited with Target Price Rs 2,386, noting the USFDA Form 483 with only two observations indicates manageable compliance risk, while FY26 is expected to deliver a second consecutive year of strong earnings growth.

Lupin: USFDA Inspection At Lupins Ankleshwar Plant Ends With Two Observations.

Alkem Lab: Cos Subsidiary Signs Deal To Buy 51%-55% Stake In Occlutech Holding AG, Progressing On Previously Announced Agreement

Dr. Reddys: DOJ Concludes Inquiry Into Foreign Corrupt Practices Act For Co Without Recommending Any Action

Dr Reddy: Goldman Sachs maintains Neutral ratings on Dr Reddy with a target price of Rs 1,225.

Gland Pharma: Goldman Sachs maintains Sell ratings on Gland Pharma with a target price of Rs 1,525.

Lupin: Goldman Sachs on Lupin Neutral, Target Price Rs 2275

Sun Pharma: Goldman Sachs on Sun Pharma Sell, Target Price Rs 1550

Biocon: Jefferies on Biocon Hold, Target Price Rs 360

Aurobindo Pharma: Eugia Pharma Introduces Pomalidomide Capsules In The U.S; Generic Version Of Pomalyst® With A Market Size Of $3.3 Billion.

DIVIS LABORATORIES LTD.: RS. 56.53 CRORES NSE BLOCK TRADE; FOR ~ 89,698 SHARES, AT RS. 6302.50

Gland Pharma: Gets Tentative USFDA Approval For Brimonidine Tartrate Eye Solution, 0.025%; Product Matches Lumify Eye Solution; US Sales Expected To Reach $39 Million By September 2025.

Glenmark Pharma: Glenmark Specialty Wins U.S. FDA Approval For Fluticasone Propionate Inhalation Aerosol, 44 Mcg Per Actuation, With 180-Day Exclusive Generic Competition. Annual Sales Reach About USD 520 Million

Biocon: Company Invests 315 Crores in Biocon Biosphere and Biocon Pharma Using OCRPS

Lupin: Maharashtra GST Department Finishes Inspection With No Negative Findings; No Effect On Cos Financials

Cipla: Forms 60:40 Joint Venture With Kemwell Biopharma To Create And Market Biologic Products, Both Partners To Invest Up To 100 Million Rupees

Cipla: New Subsidiary Established in Saudi Arabia

LAURUS LABS LTD.: RS. 59.98 CRORES NSE BLOCK TRADE; FOR ~ 563,347 SHARES, AT RS. 1064.70

Lupin: Nanomi B.V. Delays Purchase of Visufarma B.V.; Deal Now Anticipated to Finalize in April 2026, Awaiting Required Approvals

Aurobindo Pharma: US FDA Inspects Eugia Pharma Specialties Unit I; Concludes with 4 Observations

Abbott India: Partners With Novo Nordisk India To Launch Extensior And Increase Access To Semaglutide

Zydus Lifesciences: Company Successfully Develops Pembrolizumab Biosimilar FYB206; Aims for USFDA Filing with Positive Data Showing Bioequivalence to Keytruda.

Lupin: Gets Satisfactory Establishment Inspection Report From US FDA For Goa Facility, With Voluntary Action Indicated.

Aurobindo Pharma: Sarath Chandra Reddy Cleared of Liquor Scam Charges by Delhi Court

Glenmark Pharmaceuticals: Plans Launch Of Sodium Phosphates Injection USP In Three Forms Starting April 2026, With An Expected Market Size Of $66.8 Million

Aurobindo Pharma: Eugia Pharma Gets USFDA Approval For Everolimus Tablets In Various Dosages; Launch Anticipated In Q1 FY27; Projected Market Size Of $78 Million

Dr Reddys: Dam Cap Flags Possible Delay In Semaglutide Launch In Canada, Sandoz Sees Potential H2 Cy26 Timeline; Brazil/canada Approvals May Slip Vs H1 Cy26 Guidance

Laurus Lab: Motilal Oswal on Laurus Lab Maintain Buy with Target Price of Rs 1,280

Zydus Lifesciences: Company Set to Release Semaglutide Injection in India Right on Patent Expiry Date

AUROBINDO PHARMA LTD.: RS. 107.01 CRORES NSE BLOCK TRADE; FOR ~ 883,262 SHARES, AT RS. 1211.50

CITI on DR Reddys Sell, TP Rs 1070

Biocon: Gets U.S. Approval For Weight Loss Drug Liraglutide, With Market Potential Estimated At $127 Million By December 2025

Laurus Lab: NCLT Accepts Plan For Demerging Laurus Synthesis Unit-1 Into Sriam Labs And Merging Remaining Operations With Laurus Labs; Creditors Meeting Set For April 6, 2026

Lupin: Company Gets FDA Approval For Brivaracetam Oral Solution, Estimated U.S. Sales Of $135 Million

Dr Reddys Lab: Reports No Enforcement Action After SEC Investigation Concludes

Lupin: Gets European Commission Approval For Biosimilar Ranibizumab; Sandoz To Market Product In EU, Excluding Germany; Confirms Companys Dedication To Affordable Biologic Treatments

Cipla: MS on Cipla UW, Target Price Rs 1211

Torrent Pharma: Macquarie on Torrent Pharma Initiate O-P Target Price Rs 5000

Cipla: USFDA inspection At Co’s Subsidiary Pharmathen’s Facility Was Classified As Official Action Indicated.

DIVIS LABORATORIES LTD.: RS. 50.33 CRORES NSE BLOCK TRADE; FOR ~ 79,936 SHARES, AT RS. 6296.00

Zydus Lifesciences: Reports No Issues From USFDA Inspection At Its Ahmedabad Injectable Facility

Aurobindo Pharma: GST Department Requests Repayment Of ₹169.84 Crore For Wrong Refunds; Company Will Appeal And States No Significant Effect On Finances.

MANKIND PHARMA LTD.: RS. 64.80 CRORES NSE BLOCK TRADE; FOR ~ 312,486 SHARES, AT RS. 2073.80

Lupin: USFDA Inspects Lupins Largest Goa Facility, Raises Concerns About Quality Control Issues - CNBC TV18

ALKEM LABORATORIES LTD.: RS. 60.04 CRORES NSE BLOCK TRADE; FOR ~ 110,055 SHARES, AT RS. 5455.50

Zydus Lifesciences: Launches Indias First Aflibercept 2 mg Anyra™ Biosimilar For Eye Care; Partners With Regeneron And Bayer To Enhance Affordable Biologics Access For Patients With Diabetic Retinopathy And AMD.

Jefferies on Alkem Labs Buy, TP Rs 6550

Dr Reddys: Acquires Trade Marks From Mercury Pharma Group For $32.15 Million In India

Zydus Lifesciences: Gets Approval From USFDA For Bosentan Tablets, 32 mg, Which Had Annual U.S. Sales Of $9.3M

Aurobindo Pharma: USFDA Flags Off Contamination Of Samples -- USFDA Flags Off System Back Dating - Cnbctv18

Aurobindo Pharma: 25-30% Of Usa Revenues Under Risk – Unit 7 Form 483 Has Serious Risks -- Data Integrity Issues At Company’s 2nd Biggest Usa Facility- Unit 7- Cnbctv18

Eli Lilly Aims To Make India A Key Global Export Hub, Says Executive As Part Of Their Supply Chain Strategy - RTRS ( CIPLA )

HSBC on Aurobindo Pharma Buy, TP Raised to Rs 1415

Dr Reddys Laboratories: Co Exec Says The Co Hopes To Launch Its Generic Weight-Loss Drug At A 50–60% Discount To Novo Nordisk’s Wegovy -BS

Aurobindo Pharma: Faces New Inspection At Eugia Unit 1, Which Accounts For 15% Of US Sales And 25% Of ANDA Filings

Zydus Lifesciences: Company Introduces PepairTM, Indias First Affordable Drug-Free Handheld Device to Improve Respiratory Health; Aiming at Patients with COPD, Asthma, and Bronchiectasis; Cost Set at ₹990 per Unit.

IPCA Labs: Unichems Revenue Anticipated To Rise 8% To 10% After Reclaiming Market Share, Targeting 15% EBITDA Margins In 2-3 Years, Improving To 20% With European Filings. Detailed Business Guidelines To Follow After March Budget Completion

IPCA Labs: Anticipates Overall Growth Between 10% And 11%, With Promotional Branded Business Projected To Rise By 10% To 12% Long-Term. Generic And Domestic Segments Are Also Expected To Grow By 10% To 12%. The Companys EBITDA Margin May Improve By 1.5% Annually If Revenue Grows At This Rate, Indicating A 300 Basis Points Increase Over Two Years.

Lupin: Company Partners With Spektus To Distribute New Antidepressant Deslaflex In Canada

Alkem Lab: USFDA Finishes Pre-Approval Inspection At Enzene Biosciences; Issues 6 Procedural Observations But Confirms No Data Integrity Issues.

Nomura maintains buy on Lupin with a target price of ₹2,580

Goldman Sachs maintains neutral on Biocon with a target price of ₹375

HSBC maintains buy on Biocon; Cuts target price to ₹445 from ₹455

MorganStanleys call on Lupin: Equal-weight call, target price at ₹2,386/sh

Jefferies on Biocon Hold, TP Rs 360

Jefferies maintains Buy ratings on Torrent Pharma with a target price of Rs 4,690.

Citi maintains Buy ratings on Lupin, hikes target price to Rs 2,540.

Biocon: Expects Interest Savings Of Around INR 300 Crores Starting FY27 From Paying Off Structured Debt, With Current Net Debt Between $1.1B And $1.2B And A Debt-EBITDA Ratio Below 2.5X. The CRDMO Division Believes Challenges From A Single Customer Will Be Temporary, Maintaining Confidence In Long-Term Growth.

Biocon: Company Aims For Steady Growth, Better Margins, And Cash Flow-Driven Value Creation, Focusing On Improving Returns. Biocon Expects Increased Growth In Biosimilars Next Fiscal Year, With Current Year Margins Around Mid-20s And Future Margin Improvements Anticipated Without Specific Targets.

Lupin: Company Plans First 505(B)(2) Products Launch in FY27 and Exclusive XYWAV Product Launch in FY29. Injectable Portfolio, Including Dalbavancin, Eribulin, and Iron Sucrose, Expected to Exceed $100 Million in Three Years.

Lupin: Management Anticipates Double-Digit Growth of 20% to 30% in India, Outpacing Markets 7% to 8% Annual Growth. Key Growth Factors Include Resolved Past Exclusivities, Insulin Opportunities, and Upcoming Semaglutide Launch.

Lupin: India Formulations Business Expected to Be 1.2X to 1.3X Ahead of Indian Pharmaceutical Market, Boosted by Strong Sales and 80+ New Products. Company Plans to Invest $250 Million to $300 Million in Specialty Assets, Focusing on Acquisitions in Developed Markets.

Lupin: Company Raises Full-Year FY26 EBITDA Margin Guidance To 27%-28% From 25%-26%, Though Q4 Margins May Be Affected By Higher R&D Costs And Lower PLI Income. For FY27, The Company Predicts EBITDA Margins At 24%-25% While Expecting Steady Revenue Growth And A Focus On Costs Despite Risks From Product Competition And Rising R&D Expenses.

Zydus Lifesciences: Gets Final USFDA Approval For Ammonium Lactate Cream, 12%, Expected US Sales Of $15 Million

Aurobindo Pharma: FDA Approves Cos Adquey For Treating Atopic Dermatitis

Torrent Pharma: Announces Interim Dividend Of ₹29 For Each Equity Share

TORRENT PHARMA: Q3 EBITDA 10.9B RUPEES VS 9.14B (YOY) -- Q3 EBITDA MARGIN 32.94% VS 32.54% (YOY)

TORRENT PHARMA: Q3 CONS NET PROFIT 6.35B RUPEES VS 5.03B (YOY); EST 6.14B -- Q3 REVENUE 33.03B RUPEES VS 28.09B (YOY)

Alkem Laboratories: Reports 5.5% Growth In Indian Business For Q3, Falling Short Of H2FY26 Target Of Double Digit Growth.

Alkem Laboratories: To Buy 51%-55% Share In Occlutech Holding AG For €180.70 Million; Deal Expected To Close By June 30, 2026; Occlutech Specializes In Minimally Invasive Cardiac Implants With Revenue Of €49.38 Million In 2025.

ALKEM LABORATORIES LTD: CO. TO ACQUIRE 51%-55% STAKE IN OCCLUTECH HOLDING AG FOR CASH CONSIDERATION; TARGET ENTITY ENGAGED IN MINIMALLY INVASIVE CARDIAC IMPLANTS; ACQUISITION EXPECTED TO BE COMPLETED BY JUNE 30, 2026.

ALKEM LABORATORIES: Q3 EBITDA 8.3B RUPEES VS 7.6B (YOY) -- Q3 EBITDA MARGIN 22.2% VS 22.51% (YOY)

ALKEM LAB: CO DECLARED DIVIDEND OF 43 RUPEES PER SHARE

ALKEM LABORATORIES: Q3 REVENUE 37.4B RUPEES VS 34B (YOY)

ALKEM LABORATORIES: Q3 CONS NET PROFIT 6.4B RUPEES VS 6.3B (YOY); EST 6.7B

IPCA LAB: Q3 REVENUE 24B RUPEES VS 22.4B (YOY)

IPCA LAB: Q3 EBITDA 5.3B RUPEES VS 4.63B (YOY) -- Q3 EBITDA MARGIN 22.3% VS 20.62% (YOY)

IPCA LAB: Q3 CONS NET PROFIT 3.3B RUPEES VS 2.5B (YOY)

Lupin: Company Increases FY26 Margin Guidance From 25-26% To 27-28% - CNBCTv18

DIVIS LAB: CO EXPORT DOWN 30% (MOM)

Biocon: Company Plans to Launch Semaglutide in India Through Partnerships - Concall Update.

Morgan Stanley maintains Equal-weight ratings on Lupin with a target price of Rs 2,211

LUPIN: Q3 EBITDA 22.6B RUPEES VS 13.56B (YOY); EST 19.02B -- Q3 EBITDA MARGIN 31.56% VS 23.5% (YOY); EST 28%

LUPIN: Q3 CONS NET PROFIT 11.76B RUPEES VS 8.55B (YOY); EST 12.03B -- Q3 REVENUE 71B RUPEES VS 57.7B (YOY); EST 67.8B

BIOCON: Q3 EBITDA 8.3B RUPEES VS 770M (YOY) -- Q3 EBITDA MARGIN 19.97% VS 19.67% (YOY)

BIOCON: Q3 CONS NET PROFIT 1.44B RUPEES VS 251M (YOY); EST 1.69B -- Q3 REVENUE 41.7B RUPEES VS 38.2B (YOY)

ABBOTT INDIA: Q3 EBITDA 4.6B RUPEES VS 4.4B (YOY) -- Q3 EBITDA MARGIN 26.9% VS 27% (YOY)

ABBOTT INDIA: Q3 REVENUE 17.2B RUPEES VS 16.1B (YOY)

ABBOTT INDIA: Q3 SL NET PROFIT 3.8B RUPEES VS 3.6B (YOY)

Divis Labs: Company Expects Ongoing Strong Growth By Launching New Products While Losing Patent Protection On Others. Three Custom Synthesis Projects Aiming For Commercial Volumes By Q3 Or Q4 Of 2027, Subject To Regulatory Approvals.

Divis Labs: Projects Similar Capex For FY26, Excluding Custom Synthesis Project. Management Optimistic About New Products Boosting Margins And Profitability Within A Year.

Divis Labs: Plans Custom Synthesis Projects Aiming for Commercial Volumes by 2027. The Company Targets a Gross Asset Turnover Ratio of 1.5 to 1.8 Over the Next Four to Five Years.

Divis Labs: Expects Raw Material Pricing And Availability To Stay Generally Stable For Six Months, While Nutraceuticals Segment To Continue Its Strong Performance.

CITI on Divis Lab Buy, TP Rs 9140

Goldman Sachs maintains Neutral ratings on Divis Lab, cuts target price to Rs 6,050.

Jefferies maintains Buy ratings on Divis Lab, hikes target price to Rs 8,100.

Zydus Lifesciences: Settles Patent Dispute With Astellas Over Myrbetriq, Paying $120 Million, While Continuing Sales In The US For Mirabegron.

Zydus Life: SC refuses to stop Zydus Life from selling biosimilar of Nivolumab -- SC asks ER Squibb to conduct mapping of Zydus Life pdt, move HC accordingly

Zydus Life: SC refuses to stop Zydus Life from selling biosimilar of Nivolumab -- SC asks ER Squibb to conduct mapping of Zydus Life pdt, move HC accordingly

DIVIS LABORATORIES: Q3 EBITDA 8.9B RUPEES VS 7.4B (YOY) -- Q3 EBITDA MARGIN 34.18% VS 32% (YOY)

DIVIS LABORATORIES: Q3 REVENUE 26B RUPEES VS 23B (YOY)

DIVIS LABORATORIES: Q3 CONS NET PROFIT 5.8B RUPEES VS 5.8B (YOY); EST 6.26B

Aurobindo Pharma: PLI Plant Set To Produce Over 10,000 Metric Tonnes Annually, Aiming For 65% To 70% Output By March 26. Vizag Injectable Facility Filed Three Products, Ten More On The Way, Anticipating Slow Commercial Launch In FY27 And Full Earnings From FY28 For Key Cartridge Line Products.

Aurobindo Pharma: US Dayton Facility Expected To Boost Revenues From FY27, Raleigh Facility On Track For Regulation Approval. OSD China Facility To Reach EBITDA Breakeven By Q4 And Will Significantly Impact EBITDA Next Year, Aiming For 2 Billion Units Capacity Annually.

Aurobindo Pharma: Management Confident in Sustaining Growth and Meeting EBITDA Margin Goal of 20% to 21% For FY26. European Revenue Expected to Surpass EUR 1 Billion By FY26, Fueled by Strong Execution and More Products.

Citi stays Sell on Aurobindo Pharma; TP Rs. 1,020.

Aurobindo Pharma: US FDA Finds 9 Procedural Issues After Inspecting Aurobindo Pharmas Unit-VII in Telangana.

Zydus Life: Company Plans FDA Filing For Saroglitazar Magnesium, Starts Phase III Trials For Second Biosimilar In India, And Phase II Trials For Bivalent Type Four Conjugate Vaccine. The Company Aims For Keytruda Biosimilar Launch By 2028-2029, Targeting To Be The First In Market, Also Joining The First Wave Of GLP-1 Launches In India.

Zydus Life: Cos CDMO Business From Agenus Set To Start Sales In H2 FY27, Aiming For Over INR 100M In Two To Three Years. Vaccines Target Over INR 1,000 Crore In Three To Four Years. Other Costs Expected Between INR 1,750 - INR 1,800 Cr With Agenus Contributing About INR 20 Million Annually, Plus Significant SARO Launch Costs In FY27.

Zydus Life: Expects Ongoing Growth In U.S. Business For FY27 Thanks To New Product Launches And Exclusive Chances Later This Year. Indias Business Is Set To Experience Double-Digit Growth, Fueled By Innovative Brands, A Rising Chronic Mix, And Upcoming GLP-1 Launches.

Zydus Life: Expects Over 23% EBITDA Margin For Q4 FY26 Without Revlimid Revenue, Plans R&D Spending At 7.5%-8% Of Revenue For FY26 With Some Variability In Q3, Anticipates Ongoing 20%+ Growth In International Formulation Business.

AUROBINDO PHARMA LTD.: RS. 58.35 CRORES NSE BLOCK TRADE; FOR ~ 522,061 SHARES, AT RS. 1117.70

WOCKHARDT: Q3 REVENUE 8.9B RUPEES VS 7.2B (YOY)

WOCKHARDT: Q3 EBITDA 1.77B RUPEES VS 1.28B (YOY) -- Q3 EBITDA MARGIN 19.9% VS 17.75% (YOY)

WOCKHARDT: Q3 CONS NET PROFIT 590M RUPEES VS 140M (YOY)

Zydus Lifesciences: Co Management States That In The Fourth Quarter, The Co Will Deliver More Than 23% Ebitda Margins -Concall Updates

Zydus Lifesciences: Co Management Says That Despite Revlimid Sales Tapering Off From Next Quarter, The Co Expects Growth In Us Sales This Year And Next Year -Concall Updates

Zydus Lifesciences: Co Management Says That It Sees 20%+ Growth In The International Business Continuing In The Near Future -Concall Updates

Ajanta Pharma: Denies Any Involvement In The Acquisition Of Restaurant Brands Asia, Refuting Recent Economic Times Rumors.

MANKIND PHARMA: OPERATION CONDUCTED FROM FEBRUARY 03 TO FEBRUARY 08, 2026 -- BUSINESS OPERATIONS OF BSV CONTINUED AS USUAL DURING SEARCH

Mankind Pharma: Search And Seizure/Inspection Operation Conducted By Gst Department At Bharat Serums And Vaccines -- Unit Operations Continued As Usual During Inspection

Zydus Lifesciences: India Formulations Growth At 18.2% (YoY)

Zydus Lifesciences: North America Formulations Growth At 16.4% (YoY)

ZYDUS LIFESCIENCES: Q3 EBITDA 18.2B RUPEES VS 14B (YOY) -- Q3 EBITDA MARGIN 26.5% VS 26.3% (YOY)

ZYDUS LIFESCIENCES: Q3 REVENUE 67.8B RUPEES VS 52.7B (YOY)

ZYDUS LIFESCIENCES: Q3 CONS NET PROFIT 10.4B RUPEES VS 10.2B (YOY); EST 9.95B

SUN PHARMACEUTICAL INDUSTRIES LTD.: RS. 56.40 CRORES NSE BLOCK TRADE; FOR ~ 330,164 SHARES, AT RS. 1708.20

Laurus Labs Ltd.: Rs. 25.89 Crores Nse Block Trade; For ~ 270,456 Shares, At Rs. 957.20

CIPLA: Co Reports No Negative Findings From GST Department Inspection in Maharashtra.

IPCA Laboratories: API Manufacturing Facility Gets "Voluntary Action Indicated" Status From US FDA; Facilitys Compliance With CGMP Is Considered Minimally Acceptable.

Aurobindo Pharma: US FDA Inspects Eugia Pharma Unit-III, Finds 11 Procedural Issues

Alkem Laboratories: Board Supports Merging Alkem Medtech Ortho Private Limited With Alkem Medtech Private Limited, Awaiting NCLT Approval and Shareholder Consent.

Biocon: Fitch Changes Biocon Biologics Outlook To Positive And Confirms IDR At BB-

Zydus Lifesciences: Gets USFDA Orphan Drug Status For Desidustat To Treat Sickle Cell Disease, Which Could Lead To Seven-Year Exclusive Marketing Rights After Approval.

Gland Pharma: Company Gets USFDA Approval For Zoledronic Acid Injection In 4 MG/100 ML Single-Dose Bags; Product Targets Hypercalcemia Of Malignancy And Multiple Myeloma; US Sales Expected To Reach USD 6.7 Million By November 2025.

Piramal Pharma: Cos Overseas Unit Piramal Critical Care Partners With Blue-Zone Technologies To Capture, Collect, And Recycle Waste Anaesthesia Gas

JB Chemicals: Announces Interim Dividend Of ₹12.70 Per Share

JB Chemicals: Narayan Saraf Steps Down As CFO Of Co

Cipla: Company Reports Tax Department Begins Inspection At Its Facilities, No Financial Impact Expected

Divis Lab: Major API Opportunities Experience Significant Slowdown, Divis Remains Key Supplier for These APIs.

Lupin: Company Launches Topiramate Extended-Release Capsules In The U.S. With Estimated Annual Sales Of USD 164 Million

Zydus Lifesciences: Gets Tentative USFDA Approval for Dapagliflozin Tablets, 5 mg and 10 mg, for Treating Type 2 Diabetes with Annual US Sales Reaching US$ 10.49 Billion

MANKIND PHARMA: Q3 EBITDA 9.19B RUPEES VS 8.30B (YOY) -- Q3 EBITDA MARGIN 25.76% VS 25.7% (YOY)

MANKIND PHARMA: Q3 REVENUE 36B RUPEES VS 32B (YOY)

MANKIND PHARMA: Q3 CONS NET PROFIT 4.1B RUPEES VS 3.8B (YOY); EST 5.1B

Torrent Pharmaceuticals Ltd.: Rs. 24.83 Crores NSE Block Trade; for ~ 61,261 Shares, at Rs. 4053.50

Glenmark Pharma: Seeks Regulatory Approvals with Two ANDAs Submitted for North America in Q3 and Three More Planned for Next Quarter, Including Generic Flovent 110 and Two Generic Nasal Sprays.

Glenmark Pharma: Plans Expansion With New Approvals. The US division anticipates strong growth in Q4 FY26 from respiratory product launches, including a probable FloVent 44 approval, while the Monroe site will begin commercial production in the same quarter, aiming for three annual filings. New product approvals are expected in Q4, which may boost gross margins.

Glenmark: Expects Strong End To FY26 And Good Start To "Glenmark 3.0" Growth Journey In 2027, Aiming To Meet Overall Goals. Company Targets Sustainable EBITDA Margin Of 23% For This Year and Coming Quarters, Expecting Significant Margin Increase From FY28 Due To New Innovations

Glenmark Pharma: Plans To Achieve 115 Days Of Net Working Capital By March 26, Currently At About 110 Days, And Aims To Have Zero Gross Debt By March 26. The Company Expects Annual Capital Expenditure Of INR 700-800 Crores, With INR 800 Crores Slated For Next Year Mainly For Plant Expansion And In-Licensing.

Lupin: Co Launches Dasatinib Tablets In The U.S. After FDA Approval, Available In Dosages Of 20 MG, 50 MG, 70 MG, 80 MG, 100 MG, And 140 MG; Expected Annual Sales Reach USD 930 Million.

Lupin: Forms Partnership With TB Alliance To Develop Telacebec For Treating Tuberculosis And Other Mycobacterial Illnesses, Offering Manufacturing And Regulatory Support.

Lupin: DGTR, In Its Preliminary Findings Concludes That There Is Dumping Of Ethambutol Hydrochloride Imports From China And Thailand, And Flags This As A Material Injury To Domestic Players

SUN PHARMACEUTICAL INDUSTRIES: Q3 EBITDA 49.4B RUPEES VS 40.08B (YOY) -- Q3 EBITDA MARGIN 32% VS 29.30% (YOY)

SUN PHARMACEUTICAL INDUSTRIES: Q3 REVENUE 155.2B RUPEES VS 136.7B (YOY)

SUN PHARMACEUTICAL INDUSTRIES: Q3 CONS NET PROFIT 33.6B RUPEES VS 29B (YOY)

GLENMARK PHARMA: CO HAS EXCEPTIONAL ITEM OF 1.84B RUPEES -- Q3 PBT 7.2B RUPEES VS 4.6B (YOY)

GLENMARK PHARMA: Q3 EBITDA 9B RUPEES VS 6B (YOY) -- Q3 EBITDA MARGIN 23.19% VS 18.18% (YOY)

GLENMARK PHARMA: Q3 CONS NET PROFIT 4B RUPEES VS 3.5B (YOY); EST 6.3B -- Q3 REVENUE 39B RUPEES VS 33B (YOY)

AJANTA PHARMA: Q3 REVENUE 13.7B RUPEES VS 11.46B (YOY)

AJANTA PHARMA: Q3 EBITDA 3.82B RUPEES VS 3.21B (YOY) -- Q3 EBITDA MARGIN 27.8% VS 27.99% (YOY)

AJANTA PHARMA: Q3 CONS NET PROFIT RUPEES 2.7B VS 2.33B (YOY)

Laurus Labs Ltd.: Rs. 18.49 Crores Nse Block Trade; For ~ 184,264 Shares, At Rs. 1003.60

Lupin Ltd.: Rs. 19.17 Crores NSE Block Trade; for ~ 90,749 Shares, at Rs. 2112.70

Piramal Pharma: Buys Kenalog Brand For Up To $100 Million To Boost Injectable Offerings And Support Global Expansion.

PIRAMAL PHARMA: Q3 EBITDA 1.96B RUPEES VS 3.4B (YOY) -- Q3 EBITDA MARGIN 9.16% VS 15.34% (YOY)

PIRAMAL PHARMA: Q3 REVENUE 21.40B RUPEES VS 22.04B (YOY)

PIRAMAL PHARMA: Q3 CONS NET LOSS 1.36B RUPEES VS PROFIT 37M (YOY); EST 353M

PIRAMAL PHARMA: Q3 CONS NET LOSS 1.36B RUPEES VS PROFIT 37M (YOY); EST 353M

Biocon: Company Gets VAI Status From US FDA For Andhra Pradesh Plant After Inspection From November 3 To 7, 2025

GLAND PHARMA: Q3 EBITDA 4.35B RUPEES VS 3.6B (YOY) -- Q3 EBITDA MARGIN 25.65% VS 26% (YOY)

GLAND PHARMA: Q3 CONS NET PROFIT 2.6B RUPEES VS 2.05B (YOY) -- Q3 REVENUE 16.95B RUPEES VS 13.84B (YOY)

SUN PHARMACEUTICAL INDUSTRIES LTD.: RS. 278.87 CRORES NSE BLOCK TRADE; FOR ~ 1,734,892 SHARES, AT RS. 1607.40

ALKEM LABORATORIES LTD.: RS. 58.81 CRORES NSE BLOCK TRADE; FOR ~ 101,852 SHARES, AT RS. 5774.00

Divis Labs: Jefferies on Divis Labs Buy, TP Rs 8000

Laurus Labs Ltd.: Rs. 38.01 Crores NSE Block Trade; for ~ 379,125 Shares, at Rs. 1002.70

LAURUS LABS LTD.: RS. 59.97 CRORES NSE BLOCK TRADE; FOR ~ 593,935 SHARES, AT RS. 1009.70

Cipla Ltd.: Rs. 15.48 Crores NSE Block Trade; for ~ 119,140 Shares, at Rs. 1298.90

Sun Pharma: China Stops Sales Of Sun Pharmas Dementia Drug Due To Issues Found During Remote Inspection -ET

Lauras Labs: Company Aims for Strong Operational Growth in Financial Year 2026, Anticipates Stable Gross Margins Around 60% for Upcoming Quarter and Next Financial Year.

Cipla: HSBC on Cipla Downgrade to Hold, TP cut to Rs 1285

Cipla: Jefferies on Cipla Downgrade to U-P, TP cut to Rs 1170

Wockhardt: Company Reports Successful Phase 3 Trial For New Antibiotic Foviscuf® (WCK 4282) Matching Effectiveness Of Meropenem; Achieved High Clinical Cure Rate Of 93.23%.

Torrent Pharmaceuticals: Raises Its Shareholding In JB Chemicals To 48.75% By Purchasing 378,200 Shares

Zydus Lifesciences: Reports USFDA Inspection Completed At Zydus Unit-2 Plant In Ankleshwar With 3 Observations Made

Torrent Pharma: U.S. FDA Inspects Dahej Facility With No Issues Found

Aurobindo Pharma: Co Expands Footprint With New Wholly Owned Philippines Subsidiary

Cipla: Co May Venture Into Semaglutide Generics Soon, Partnered With Eli Lilly For Mounjaro Under Yurpeak Brand.

CIPLA: Co In Discussions With Several Partners For CAR-T Cell Therapy Products.

LAURUS LABS: 9M FY26 CDMO 14.9B VS 10.44B (YOY)

LAURUS LABS: Q3 REVENUE RUPEES 17.8B VS 14.1B (YOY)

LAURUS LABS: Q3 EBITDA 4.8B RUPEES VS 2.86B (YOY) -- Q3 EBITDA MARGIN 27% VS 20.21% (YOY)

LAURUS LABS: Q3 CONS NET PROFIT RUPEES 2.52B VS 923M (YOY)

Cipla: Co CEO Says Upcoming Launches To Cushion Grevlimid Rev. Decline

Cipla: Co CEO Says Upcoming Launches To Cushion Grevlimid Rev.

CIPLA: QUARTERLY BUSINESS WISE SALES PERFORMANCE - NORTH AMERICA SEES A DEGROWTH OF 22% (YOY)

Alkem Laboratories: Co To Consider Q3 Results On Feb 13

CIPLA: Q3 REVENUE 70.7B RUPEES VS 70.7B (YOY); EST 72.85B

CIPLA: CO HAS AN EXCEPTIONAL ITEM OF 2.8B -- Q3 PBT 11.7B VS 19B (YOY)

CIPLA: Q3 EBITDA 12.55B RUPEES VS 19.8B (YOY); EST 15.9B -- Q3 EBITDA MARGIN 17.74% VS 28.11% (YOY); EST 22%

CIPLA: Q3 CONS NET PROFIT 6.76B RUPEES VS 15.7B (YOY); EST 11.3B

Sun Pharma Gets Approval To Make And Sell Generic Semaglutide Injection In India For Weight Management; Brand Name NovelTreat Launching After Patent Ends; Five Dose Options Offered.

Zydus Lifesciences: Company Introduces Worlds First Biosimilar Nivolumab, Tishta™, In India For Various Cancers; Priced At ₹28,950 And ₹13,950, Roughly 25% Of Original Drug Price; Aims To Help Over 500,000 Patients.

DR Reddys: CLSA on DR Reddys Upgrade to hold, target price raised to Rs 1210

DR Reddys: CITI on DR Reddys Sell, target price Rs 1070

Dr Reddys Lab: Guidance - Abatacept biosimilar is expected to launch in the US (IV product) by the end of calendar 2026 and subQ by January or February 2028, with a European launch for both IV and subQ planned for July 2027 into a $2 billion addressable market.– Concall Update

Dr Reddys Lab: Guidance - US launch timelines for biosimilars are delayed: Denosumab is likely in Q2 FY27 or later, and Rituximab is unlikely within the next six months due to regulatory processes.– Concall Update

Dr Reddys Lab: Guidance - Semaglutide is slated for launch in India on March 21st, Canada between late February and May, and Brazil and Turkey around July, with pricing anticipated at the lower end of the $20-$70 spectrum due to expected competition.– Concall Update

Dr Reddys Lab: Guidance - The India business is expected to sustain "15% plus" growth, with potential for higher, and Emerging Markets (including Russia) are projected to maintain "healthy double-digit" growth.– Concall Update

Dr Reddys Lab: Guidance - Management expects the underlying EBITDA margin to be around 25% after adjusting for one-time provisions.– Concall Update

Biocon: Company Achieves 98% Ownership In Biocon Biologics Equity Shares

Dr Reddys: Plans To Sell 12 Million Units Of Generic Semaglutide In Its First Year Of Release

Dr Reddys: Co-Executive Anticipates Semaglutide Launch First in India, Then in Emerging Markets, and Finally in Canada

Dr Reddys: Company Executive Announces Plans to Launch Semaglutide in March 2026 and Has Obtained Local Manufacturing Licenses for the Injection

Dr. Reddys: Gets Approval For Semaglutide Injection Marketing In India From DCGI

DR. REDDYS LABORATORIES: Q3 EBITDA 18.9B RUPEES VS 22.7B (YOY); EST 18.03B -- Q3 EBITDA MARGIN 21.56% VS 27.17% (YOY); EST 21.8%

DR. REDDYS LABORATORIES: Q3 CONS NET PROFIT 12.1B RUPEES VS 14.1B (YOY); EST 11.32B -- Q3 REVENUE 87.5B RUPEES VS 83.8B (YOY); EST 82.73B

Dr Reddy: Records Quarterly Charge Of 1.17 Billion Rupees From New Labor Codes

Sun Pharma: Jefferies maintains Buy on Sun Pharma with a target price of Rs 2,100.

Zydus Lifesciences: Co Is Evaluating The Acquisition Of A Majority Stake In The Us Based Ardelyx Inc, With The Deal Likely To Be Valued At 2-2.5B USD; Ardelyx Is A Biopharma Firm That Is Valued At Usd 1.7B (As On 20th Jan) On The Nasdaq -Mint

Lupin: Partners With :Galenicum For Semaglutide Licensing And Supply In 23 Nations

Sun Pharmaceutical Industries Ltd.: Rs. 20.56 Crores NSE Block Trade; for ~ 125,250 Shares, at Rs. 1641.20

Laurus Labs Ltd.: Rs. 24.64 Crores NSE Block Trade; for ~ 232,444 Shares, at Rs. 1060.10

JB Chemicals: Maintains Operating Margin Forecast Between 27% To 29% For Fiscal Year 2026, With Q4 Gross Margins Estimated To Be 60% To 69% And Full-Year EBITDA Margins Near 28% To 29%.

JB Chemicals: Predicts International Business To Grow In High Single Digits By FY 26, With Q4 Expected To Mirror Q3s Double-Digit Growth Thanks To Strong Orders. The CDMO Sector Is Anticipated To Expand By About 10% To 12% For FY 27, Targeting Quarterly Earnings Of Around Rs. 115 Cr To 120 Cr This Year.

JB Chemicals: Predicts Operating Margins Of 27% To 29% For FY 26, With Domestic Growth Expected To Outperform Indian Pharma Market By 200-300 BPS, Continuing Momentum Into Q4.

Torrent Pharma: Issues ₹1,500 Crore Commercial Paper On NSE At 7.20% For 337 Days, Maturity Date December 22, 2026

JB Chemicals And Pharma: Co Management Says That The Merger With Torrent Pharma Could Wrap Up In Q4 - Concall Updates

Jb Chemical And Pharma: Co CFO Says That The Sales Momentum During The Quarter Was Sustained Despite A Higher Base Last Year, And This Is Expected To Continue In Q4 -Concall Updates

Sun Pharmaceutical Industries: Co Denies Rumors Of A $10 Billion Acquisition Of Organon, Stating The Information Is Speculative And No Significant Event Needs Disclosure

LAURUS LABS LTD.: RS. 55.00 CRORES NSE BLOCK TRADE; FOR ~ 517,109 SHARES, AT RS. 1063.70

Torrent Pharma: Govt Committee Accepts Cos Phase 3 Ct Study Report On Semaglutide - CNBC Tv18

Laurus Labs Ltd.: Rs. 15.41 Crores NSE Block Trade; for ~ 144,736 Shares, at Rs. 1064.70

Laurus Labs Ltd.: Rs. 44.38 Crores NSE Block Trade; for ~ 416,394 Shares, at Rs. 1065.70

Cipla: Nomura Reports Lanreotide Is One Of CIPLAs Top U.S. Products With Estimated Yearly Sales Of USD 120–150M; Resupply In H1 FY27 Now Seems Unlikely.

Cipla: Nomura Reports Full Class II Recall Of Lanreotide Injection In The U.S. Due To Rising Quality Issues.

LAURUS LABS LTD.: RS. 119.25 CRORES NSE BLOCK TRADE; FOR ~ 1,116,535 SHARES, AT RS. 1068.00

Sun Pharma: Co Plans To Expand In The U.S. By Acquiring Organon For $10 Billion - ET

JB CHEMICALS & PHARMA: Q3 EBITDA 2.7B RUPEES VS 2.45B (YOY) -- Q3 EBITDA MARGIN 27.20% VS 26.86% (YOY)

JB CHEMICALS & PHARMA: Q3 CONS NET PROFIT 1.79B RUPEES VS 1.56B (YOY) -- Q3 REVENUE 9.9B RUPEES VS 9B (YOY)

Alkem Laboratories Ltd.: Rs. 15.32 Crores NSE Block Trade; for ~ 26,165 Shares, at Rs. 5856.00

Mankind Pharma Ltd.: Rs. 22.27 Crores NSE Block Trade; for ~ 100,092 Shares, at Rs. 2225.10

Cipla: Nuvama on Cipla Downgrade to reduce, target price cut to Rs 1360

Cipla: Nomura on Cipla Buy, target price Rs 1770

Cipla: MS on Cipla UW, target price cut to Rs 1292

Sun Pharma: Co Releases Unloxcyt™ (Cosibelimab-IPDL) For Advanced Cutaneous Squamous Cell Carcinoma.

Zydus Life: Company Gets Final USFDA Approval For Eltrombopag Tablets, Which Reported Annual Sales Of USD 1,262.5 Million

Cipla: USFDA Gives Form 483 To Pharmathens Greece Plant; Lanreotide Production Paused, Supply Expected Back In First Half Of FY27

Dr. Reddy’s: co Launches First Generic Version Of Olopatadine Hydrochloride Eye Drops, 0.7%, In The U.S

DR. REDDYS LABORATORIES LTD.: RS. 50.40 CRORES NSE BLOCK TRADE; FOR ~ 425,284 SHARES, AT RS. 1185.00

Ipca Laboratories Ltd.: Rs. 18.13 Crores NSE Block Trade; for ~ 120,447 Shares, at Rs. 1504.90

Ajanta Pharma: co Creates New Subsidiary In Ireland Named Ajanta Pharma Ireland

Gland Pharma: Co Exports Up 62% MoM

Divis Lab: Dec Export Data Strong Up 49% (MoM) At $117m

Biocon: Co QIP of $460M or Rupees 41.6B -- SBI, ICICI Funds Lead

IPCA Laboratories Ltd: Will Sell Entire Stake In Bayshore Pharmaceuticals USA Inc. To Centaur Pharmaceuticals USA Inc. For $400,000; The Sale Aims To Cut Compliance Costs As Bayshore Is Currently Not Operating

Zydus Lifesciences: FDA Approves Zycubo® For Menkes Disease Treatment; Its The First Approved Therapy In The U.S. Showing Significant Survival Improvement.

Biocon: Sets Floor Price At 387.74 Rupees For Each Share

Aurobindo Pharma Limited: Curateq Biologics Gets Approval From Health Canada For Dyrupeg Biosimilar, Confirms It Meets Safety, Efficacy, And Quality Standards

Mankind Pharma: Co To Consider Q3 Results On Feb 3

Cipla Ltd.: Rs. 15.11 Crores NSE Block Trade; for ~ 103,457 Shares, at Rs. 1460.80

LAURUS LABS: CO TO CONSIDER Q3 RESULTS ON JAN 23

Torrent Pharmaceuticals Ltd.: Rs. 28.91 Crores NSE Block Trade; for ~ 72,154 Shares, at Rs. 4006.30

Alkem Laboratories: Introduces Renocia Cyclical Therapy, A Nutritional Supplement Kit For Hair Growth Aimed At Both Men And Women With Vegetarian Ingredients, Featuring A Weekly Plan For Better Nutrient Absorption.

Dr. Reddys Lab: CITI on DRL Sell, Target Price Rs 990

Dr Reddy’s Labs: Citi maintains Sell on DrReddy with Price Target of Rs 990

Ajanta Pharmaceuticals Ltd.: Rs. 17.33 Crores NSE Block Trade; for ~ 60,708 Shares, at Rs. 2854.50

CIPLA: US FDA Issues Form 483 To Pharmathens Rodopi Facility For Lanreotide Manufacturing, Highlighting 9 Observations Including Data-Integrity Issues That May Affect Ciplas Significant US Revenue From Lanreotide

Wockhardt: Company Submits WCK 5222 Marketing Application To European Medicines Agency.

Lupin: Company Approves Mr. Anand Kripalus Appointment As Additional Non-Executive Independent Director Starting On February 01

Biocon: Biocon Biologics Aims To Grow Its Biosimilar Oncology Offerings

Cipla Ltd.: Rs. 15.81 Crores NSE Block Trade; for ~ 103,426 Shares, at Rs. 1528.30

Divis: CITI On Divis Buy, Target Price Rs 9140

Torrent Pharma: Cos Board Approves Issuance of Secured, Rated, Listed, Redeemable Non-Convertible Debentures Totaling Up to ₹ 12,500 Crores.

CIPLA LTD.: RS. 76.53 CRORES NSE BLOCK TRADE; FOR ~ 505,366 SHARES, AT RS. 1514.40

Biocon: Company Issues 2 Billion Rupees in Commercial Papers

Zydus Lifesciences: Auroralux S.A.S. Will Be Dissolved Without Liquidation By December 31, 2025; Its Assets And Liabilities Will Move To Zydus Medtech (France) S.A.S.; Business Operations Remain Unaffected.

DR. REDDYS LABORATORIES LTD.: RS. 70.11 CRORES NSE BLOCK TRADE; FOR ~ 564,520 SHARES, AT RS. 1242.00

DR Reddys: JP Morgan on DR Reddys UW Price Target Rs 1170

Aurobindo Pharma: Acquires Non-Oncology Prescription Business From Khandelwal Laboratories For 3.25 Billion Rupees

Wockhardt: Company Aims for European Approval of Zaynich by July 2026 -NDTV Profit

Laurus Labs Ltd.: Rs. 26.70 Crores NSE Block Trade; for ~ 240,894 Shares, at Rs. 1108.30

Dr. Reddys: Swiss Arm Gets Complete Response Letter From USFDA Regarding AVT03 Biosimilar Application

Wockhardt: Receives Fast-Track Review from European Medicines Agency for WCK 5222, Aiming at Tough Infections; This Marks Indias First New Drug for Pan-European Approval.

Alkem Lab: Alkem Wellness Pays ₹32.5 Crore To Complete ₹532.5 Crore Sale Of Trade Generics Business

Aurobindo Pharma Ltd: Plans To Buy Up To 26% Of Swarnaakshu Solar Power Private Limited, Pending State Government Approval By March 31, 2026.

Dr Reddys Laboratories: Co To Consider Q3 Results On Jan 21

Aurobindo Pharma: Government Will Soon Set Minimum Import Price for Penicillin to Boost Local API Investments Under PLI - MC

Ajanta Pharm: Motilal Oswal on Ajanta Pharm Maintain Buy with target price of ₹3,145

Lupin: Company Signs Exclusive Licensing Deal With Gan & Lee Pharmaceuticals For New GLP-1 Receptor Agonis

Aurobindo Pharma: Co Ends Deal With Biofactura Inc For BFI-751 Biosimilar, Decision Aligns With Strategic Focus; No Major Effect On Overall Biosimilars Plan

Alkem Labs: Announces Purchase of Shares in Enzene Biosciences for 3 Billion Rupees

Zydus Lifesciences: Company and Sterling Biotech Postpone API Business Deal Closure to June 30

DR Reddys: Semaglutide Is Not Approved In Canada As It Does Not Meet Regulatory Standards

Zydus Lifesciences: Company Teams Up With Bioeq For U.S. Rights To Nufymco, Nufymco BLA Gets USFDA Approval On December 18, 2025

Laurus Labs: Invests 350 Million Rupees in Laurus Bio

Biocon: Company Partners With Ajanta To Market Semaglutide In 26 Nations

Ajanta Pharma: Signs Deal With Biocon For Semaglutide Supply In 26 Countries

Aurobindo Pharma: Company Plans To Buy Extra 20% Stake In Luoxin Aurovitas Pharma, China For USD 5.125 Million; Partner In Joint Venture Is Shandong Luoxin; This Purchase Will Boost Manufacturing Capacity; Deal Expected To Finalize In 3 Months

Zydus Life: High Court Permits Co To Manufacture Semaglutide And Export It To Specific Countries

Zydus Life: HC Allows Co To Manufacture Semaglutide, Export To Some Nations

Biocon: Company Gains Complete Global Rights To Biosimilar Adalimumab By Expanding FKB In-Licensing Deal; Takes Charge Of Manufacturing And Sales; FKB Will Lower Development Expenses And Earn Royalties.

Glenmark Pharma: Glenmark Pharmaceuticals Inc., USA Introduces New Epinephrine Injection USP, 30 MG/30 ML (1 MG/ML) Multiple-Dose Vial

Biocon: Company Issues Commercial Papers Worth ₹18 Billion

Divis Laboratories: Morgan Stanley on Divis Laboratories overweight with Price Target of Rs 7541

Cipla: Signs 5-Year Marketing Deal With Pfizer For Four Brands In India

Divis Laboratories: Sees 68% Month-Over-Month And 17% Year-Over-Year Growth In Exports In US Dollar Terms

Zydus Lifesciences: Partners with Myriad Genetics to Introduce Cancer-Risk Testing in India

Biocon: Company Gets EIR With VAI Status From U.S. FDA For New Jersey Facility

Lupin: Company Partners With Neopharmed For Exclusive Licensing Of Gastroenterology Drug Plasil In Philippines And Brazil

DIVIS LABORATORIES LTD.: RS. 95.73 CRORES NSE BLOCK TRADE; FOR ~ 150,017 SHARES, AT RS. 6381.50

Aurobindo Pharma: US FDA Finishes Inspection At APL Healthcares Unit-IV; 5 Procedural Issues Noted, Company To Reply Within Set Deadlines

Sun Pharma: US FDA Inspects Cos Baska Facility, Classifying It As Official Action Indicated Status, Co Continues Production And Supply Of Approved Products To The U.S. Market And Aims For Full Compliance With Regulators.

Lupin Limited: Gets Favorable Opinion From CHMP For Biosimilar Ranibizumab; Marketing Approval Suggested For Vial And Pre-Filled Syringe Forms; Sandoz Group AG To Manage Marketing In EU

Lupin: Company Gets EIR Approval From US FDA For Nagpur Injectable Plant

Wockhardt: Company Establishes Three New Step-Down Subsidiaries in Switzerland and the USA

Glenmark Pharma: Co Signs Exclusive Deal With Hansoh Pharma For Aumolertinib Rights, Totaling Over $1 Billion Payment

Zydus Lifesciences: Sentyln Therapeutics Gets FDA Nod For CUTX-101 NDA Reapplication With New PDUFA Date

Biocon: Company Introduces Liraglutide, A Glucagon-Like Peptide-1, In The Netherlands, Marketing It As Diavorin® And Vobexoryn®; This Marks Their First EU Launch Under Their Own Brand After MEB Approval

Biocon: Company Launches Liraglutide, A Glucagon-Like Peptide-1, In The Netherland

BIOCON: CO. SIGNS SETTLEMENT AND LICENSE AGREEMENT TO COMMERCIALIZE BIOSIMILAR AFLIBERCEPT WORLDWIDE; AGREEMENT CLEARS PATH FOR LAUNCH IN UK JANUARY 2026 AND OTHER COUNTRIES BY MARCH 2026.

Dr. Reddys Lab: USFDA Finishes GMP And PAI Review At Co Srikakulam Plant; Issues Form 483 Highlighting Five Concerns

Aurobindo Pharma: US FDA Completes Inspection at Apitoria Pharmas Unit-V, Issues Form 483 with 3 Observations

Lupin: Co Manufacturing Solutions Partners With Polypeptide To Expand Global Peptide Supply Chain

MANKIND PHARMA LTD.: RS. 52.58 CRORES NSE BLOCK TRADE; FOR ~ 243,821 SHARES, AT RS. 2156.60

Dr Reddy’s: HC Bench Refuses To Stay Dr Reddy’s Export Of Semaglutide To Some Nations

Piramal Pharma: Cos Lexington Facility Gets US FDA Form-483 With Four Issues Found After GMP Inspection

Dr. Reddys Laboratories Ltd.: Rs. 32.40 Crores NSE Block Trade; for ~ 258,904 Shares, at Rs. 1251.50

Glenmark Pharma: Glenmark Pharmaceuticals Inc., USA Set To Release Leucovorin Calcium For Injection USP, Starting December 2025.

CIPLA: CO LAUNCHES YURPEAK® (TIRZEPATIDE) FOR THE TREATMENT OF OBESITY AND TYPE 2 DIABETES

Sun Pharma: Plans To Export Semaglutide Only To Countries Without Novo Nordisk Patent, Will Not Sell In India Until Patent Is Secured.

Alkem Laboratories: Malta Medicines Authority Inspects Daman Facility With No Critical Issues Found; Three Major And Several Minor Observations Need Attention.

Zydus Lifesciences: Launches Bone Health Drug Zyrifa For Cancer Patients At ₹12,495 To Help Prevent Skeletal Issues

Zydus Lifesciences: Launches Bone Health Drug Zyrifa For Cancer Patients At ₹12,495 To Help Prevent Skeletal Issues

Aurobindo Pharma: co Plans To Invest 20 Billion Rupees In Telangana Over The Next 2-3 Years

Zydus Lifesciences: Company Teams Up With Formycon To Exclusively License And Supply Keytruda Biosimilar In The US And Canada

Sun Pharma: Novo Nordisk Takes Legal Action Against Sun Pharma To Prevent Production Of Semaglutide

Dr Reddys Laboratories: Forms Partnership With Immudep SAS For Exclusive Rights To Eftilagimod Alfa, Involves $20 Million Initial Payment Plus Up To $349.5 Million In Milestone Payments And Ongoing Double-Digit Royalties On Sales.

Biocon: BOFA SEC on Biocon Buy, Price Target Rs 455

Biocon: Goldman Sachs on Biocon Neutral, Price Target Rs 375

Biocon: Avendus Spark on Biocon maintains Add with Price Target of Rs 435

Biocon: Board Greenlights Fundraising of Up to ₹4,500 Crore Through Various Securities for Cash to Mylan

Biocon: Company Gets Tentative FDA Nod For Carbidope And Levodopa Extended-Release Capsules For Parkinsons Disease

IPCA Labs: Company Reports US FDA Issues Form 483 Listing Three Concerns at Tarapur Facility.

Lupin: Company Gets Tentative Approval From U.S. FDA For Siponimod Tablets, Market Potential Estimated At $200 Million

Cipla: Completes Full 100% Takeover Of Inzpera Healthsciences By Acquiring Remaining Stake

TORRENT PHARMACEUTICALS LTD.: RS. 88.09 CRORES NSE BLOCK TRADE; FOR ~ 231,969 SHARES, AT RS. 3797.50

Lupin: Company Partners with Valorum for Exclusive Licensing Deal of Biosimilar Armlupeg in the U.S.

Zydus Lifesciences: Company Gets USFDA Inspection Report for Jarod Injectable Facility, Marked as Voluntary Action Indicated After GMP Review.

Dr Reddy: Jefferies on Dr Reddy maintains Underperform with Price Target of Rs 1130

Biocon: Plans To Invest In Biocon Biologics By Purchasing Securities From Shareholders On December 6

Biocon: Company To Explore Raising Funds Through Commercial Paper Or Issuing Shares on Dec 6

DR. REDDYS LABORATORIES LTD.: RS. 113.93 CRORES NSE BLOCK TRADE; FOR ~ 888,017 SHARES, AT RS. 1283.00

Dr Reddy’s Laboratories: Delhi HC Allows Company to Manufacture and Export Its Version of Semaglutide in India; Case Was Filed by Novo Nordisk for Patent Infringement – ET

Sun Pharmaceutical Industries: Co Unit Approves ₹3,000 Crore Investment For New Manufacturing Plant In Madhya Pradesh

Dr. Reddys: Aurigene Oncology Reports Positive Early Results From Phase 1 Study Of AUR112, An Oral Drug For Relapsed Lymphoid Cancers, With A 63.6% Response Rate - RTRS

Biocon: Company Confirms Launch Date For Denosumab Biosimilars In Europe And Worldwide; Agreement With Amgen Allows For Sales; Vevzuo® And Evfaxy® Set To Release On December 2, 2025

Dr Reddys: HSBC on Dr Reddys Buy, Price Target Rs 1430

Wockhardt Ltd: US FDA Approves New Drug Application For Zaynich Antibiotic; First NDA Approval For An Indian Pharma Company; Zaynich Given Fast Track Status For Urgent Needs

Sun Pharma: CITI on Sun Pharma Buy, Price Target Rs 2180

Lupin: CITI on Lupin Buy, Price Target Rs 2260

Laurus Labs: CITI on Laurus Labs Sell, Price Target Rs 590

Sun Pharmaceutical Industries: Launches Ilumya® In India For Moderate-To-Severe Plaque Psoriasis, Clinical Study Shows Major Skin Improvement In Patients, Ilumya Approved In 35 Countries

Glenmark Pharmaceuticals: U.S. FDA Finishes Inspection At Cos Chhatrapati Sambhajinagar Facility With No Issues Found.

Lupin: Company And Several PE Firms, Including TPG And EQT, Are In Talks To Buy UKs Biggest Nutraceutical Firm Vitabiotics -ET

Lupin: Company, TPG Capital, and EQT are Negotiating to Purchase Family-Owned Vitabiotics. - ET

Lupin: Company Gains U.S. FDA Approval For Biosimilar Armlupeg (Pegfilgrastim-Unne) With Estimated Annual Sales Of $1.295 Billion In The U.S.

Zydus Life: Co Signs $100 Million Agreement With Afghan Firm For Medicine Exports And Future Local Production

Zydus Lifesciences: Co Gets Tentative USFDA Nod For Empagliflozin And Linagliptin Tablets.

SUN PHARMACEUTICAL INDUSTRIES LTD.: RS. 103.04 CRORES NSE BLOCK TRADE; FOR ~ 569,649 SHARES, AT RS. 1808.90

Glenmark Pharmaceuticals: Gets VAI Status From U.S. FDA For Monroe Facility, Resuming Commercial Manufacturing

Sun Pharma: MS on Sun Pharma OW, Target Price Rs 2026

CIPLA: Toxic Air Boosts Respiratory Drug Sales, Segment Grows 14.7% In October; CIPLA Moves Up to Second Place, Overtaking Abbott

LAURUS LABS LTD.: RS. 53.85 CRORES NSE BLOCK TRADE; FOR ~ 550,942 SHARES, AT RS. 977.40

Zydus Lifesciences: Company Forms Exclusive Deal with RK Pharma for New Oncology Care Product; RK Pharma Will Produce While Zydus Manages NDA Filing and Sales in the US; Product Aims at 6.2 Million Unit Market Potential.

Aurobindo Pharma: Pen-G Prices Decrease Due To Competition From Chinese Imports, Struggling To Increase Pen-G Production.

Aurobindo Pharma: Macquarie on Aurobindo Pharma Maintain Underperform with TP of Rs 1010

Sun Pharmaceutical Industries: Gets FDA Approval For Updated Label Of Unloxcyt™ (Cosibelimab-Ipdl) For Advanced Skin Cancer; Long-Term Data Indicates Better Clinical Results And Lasting Responses; Commercial Launch Expected In Early 2026

Zydus Lifesciences: Co Gets USFDA Final Approval for Verapamil Hydrochloride Extended-Release Tablets

Glenmark Pharmaceuticals: Introduces First Nebulized Triple Treatment For COPD That Combines Glycopyrrolate, Formoterol, And Budesonide To Enhance Lung Function And Control Symptoms

Lupin: Jefferies on Lupin Buy, target price Rs 2300

Dr. Reddys: Gets Approval From European Commission For AVT03, A Biosimilar Of Prolia® And Xgeva®

Abbott India: Government Approves Kartik Rajendran As New Managing Director Of Co

Alkem Labs: Health Ministry Inspects Sikkim, India Manufacturing Facility, Concludes With No Major Observations.

MANKIND PHARMA LTD.: RS. 70.02 CRORES NSE BLOCK TRADE; FOR ~ 314,302 SHARES, AT RS. 2227.90

MANKIND PHARMA LTD.: RS. 70.02 CRORES NSE BLOCK TRADE; FOR ~ 314,302 SHARES, AT RS. 2227.90

MANKIND PHARMA LTD.: RS. 225.14 CRORES NSE BLOCK TRADE; FOR ~ 1,001,959 SHARES, AT RS. 2247.00

Piramal Pharma: Co Unit Bioconjugates Facility in Grangemouth, UK, has been granted updated GMP certificates from MHRA.

Biocon: Gets USFDA Green Light For Tofacitinib Extended-Release Tablets; Final Approval For 11mg Strength And Tentative Approval For 22mg Strength; Used For Rheumatoid Arthritis And Other Conditions.

Glenmark Pharma: HSBC on Glenmark Pharma Buy, target price cut to Rs 2110

Glenmark Pharmaceuticals: Gets Approval To Market Winlevi® Cream In 15 European Countries For Treating Acne In Adults And Teens.

Cipla: Eli Lilly Receives Approval To Market Donanemab In India

Glenmark Pharma: Aims For 12-15% Revenue Growth With Initial EBITDA Margins Of 23%, Planning To Reach 25% Plus Later. They Target Return Ratios Of 25-30% ROCE And 20-25% ROE. The IGI Subsidiary Plans Annual Spending Of $70-75 Million

Glenmark Pharma: Sets Quarterly Revenue Goals Of ₹1,150-1,200 Crores From Q3 FY26 And Over ₹4,800 Crores For FY27, Targeting Total Revenue Of ₹17,000-18,000 Crores For FY27.

Glenmark Pharma: Co Management Says That It Aims To Grow Revenues 15% Yearly Going Forward -- Co Says That They Aim On Their EBITDA Margin Moving Up To 25% Going Forward And The Co Is Aiming To Be Gross Debt Free In The Coming Time - Concall Updates

Glenmark Pharma: Co Management Says That In FY26 The Co Will Surely Be A Gross Debt Zero Co - Concall Updates

Glenmark Pharma: Co Expects Sales in India to Recover from Q3, Aiming for ₹1150-1200 Crore From Q3 This Year and ₹4800 Crore for the Next Year -Concall Updates

Glenmark Pharma: Co Is Targeting A Revenue Between 17,000 And 18,000 Crores By The End Of FY27 - Concall Updates

Lupin: Company Confirms FDA Inspection Closure Of Nagpur Unit-1 With No Issues Found

Glenmark Pharmaceuticals: Co Guides For Re-Rated Profitability Post AbbVie Biotech Deal; Consolidated EBITDA Margin To Rise To ~23 % From H2 FY26; US $ 1.9 Bn AbbVie Partnership Funds R&D And Debt Reduction; Focus On High-Growth Therapies (Respiratory, Oncology, Dermatology); Expanding CRDMO Capabilities And Global Commercialization In Emerging Markets To Drive Sustained Growth

GLENMARK PHARMA: Q2 EBITDA 23.6B RUPEES VS 6.1B (YOY) -- Q2 EBITDA MARGIN 39.03% VS 17.88% (YOY)

GLENMARK PHARMA: Q2 CONS NET PROFIT 6.1B RUPEES VS 3.54B (YOY) -- Q2 REVENUE 60.5B RUPEES VS 34B (YOY)

Aurobindo Pharma: US FDA Completes Bhiwadi Unit-II Inspection With 9 Procedural Observations

Dr. Reddy’s: Co Srikakulam API Plant Clears USFDA GMP Inspection With Zero Observations

Divis Laboratories: US-FDA Ends Inspection Of Unit-I Facility With Zero 483 Observations; Inspection Took Place From November 10 To November 14

Glenmark Pharma: Co Settles Final Zetia–Vytorin Antitrust Case With UnitedHealthcare For $11M, Fully Resolving All Litigation

Zydus Lifesciences: Gets Final USFDA Approval For Leuprolide Acetate Injection, 14 Mg/2.8 Ml For Advanced Prostatic Cancer Treatment; Annual US Sales Estimated At $69 Million.

Aurobindo Pharma: Telangana Unit Gets Establishment Inspection Report Marked "Voluntary Action Indicated.

Ipca Labs: Guidance - Consolidated Ebitda Margin Guidance Has Been Raised, Expected To Be 1% Better Than Earlier 20% Guidance- Concall Update

Ipca Labs: Guidance - Api Business Expected To Grow 14-15% For The Full Year -- R&D Spend Guidance Is Around 4% Of Turnover For Current Year, Increasing To 4.5-4.75% Next Year- Concall Update

Ipca Labs: Guidance - For Domestic Formulation Business, Guidance Is 10-11% Growth For The Full Year -- For Generic Formulations, Expecting 8-9% Growth In H2 Fy26- Concall Update

Alkem Labs: Nomura on Alkem Labs Buy, target price Rs 6860

Alkem Labs: HSBC on Alkem Labs Hold, target price raised to Rs 5170

Lupin: Unveils Risperidone Long-Acting Injectable With 180-Day CGT Exclusivity In The U.S., Marking The First Launch From Its PrecisionSphere Platform.

Zydus Lifesciences: USFDA Inspection Ends With Two Observations At Zydus Oncology Injectable Plant In Ahmedabad

Zydus Life: Co Gets Usfda Final Nod For Diroximel Fumarate 231Mg Capsules Used In Multiple Sclerosis

Zydus Lifesciences: Company Gets Final USFDA Approval For Diroximel Fumarate Delayed-Release Capsules, 231 Mg; This Product Is For Treating Relapsing Multiple Sclerosis; Expected Annual Sales Of USD 999.4 Million In The US

ALKEM LABORATORIES: Q2 REVENUE 40B RUPEES VS 34.1B (YOY)

ALKEM LABORATORIES: Q2 EBITDA 9.1B RUPEES VS 7.5B (YOY) -- Q2 EBITDA MARGIN 22.8% VS 22.04% (YOY)

ALKEM LABORATORIES: Q2 CONS NET PROFIT 7.7B RUPEES VS 6.9B (YOY)

IPCA LABORATORIES: Q2 REVENUE 25.6B RUPEES VS 23.55B (YOY)

IPCA LABORATORIES: Q2 EBITDA 5.44B RUPEES VS 4.4B (YOY) -- Q2 EBITDA MARGIN 21.32% VS 18.7% (YOY)

IPCA LABORATORIES: Q2 CONS NET PROFIT 2.8B RUPEES VS 2.3B (YOY)

Zydus Lifesciences: Company Gets CE Mark for Surgical Robot Andy, Opens EU Market Potential, Combines Navigation Tech with Robotic Help.

Biocon: Co Managing Director States No Board Action Taken Yet on Biocon Biologics Merger.

Lupin: Company Gets EIR From U.S. FDA For Aurangabad Facility

Sun Pharma: Co Shares Results On Utreglutide At ObesityWeek 2025, Showing Weight Loss Of Approximately 6.8% And A 10% Decrease In LDL; Drug Well Tolerated. Phase 1B/2A Data From AHA 2025 Indicates 8% Weight Loss At Week 14 Along With Lower Liver Fat In Post-Menopausal Women

Biocon: Co Management Anticipates Margins of Around 40% from October to March, -Concall Updates

MANKIND PHARMA LTD.: RS. 51.88 CRORES NSE BLOCK TRADE; FOR ~ 234,133 SHARES, AT RS. 2215.90

Sun Pharma: Cos Fibromun Combo Shows Good Results Even Though It Did Not Meet Primary Goal In Fibrosarc Trial; Complete Findings To Be Shared At 2026 Scientific Conferences.

JB Chemicals & Pharmaceuticals: Co Guides For Sustained Double-Digit Growth With Q2FY26 Revenue ₹962Cr (+10.4% YoY) And EBITDA Margin 24.2%; India Business Up 11% YoY With Strong Growth In Chronic And Gastro Segments; Expanding Global CDMO And API Capabilities; Launching 10+ New Products In FY26 Including Cardiac And Diabetes Therapies; Focused On R&D, Cost Optimization, And Export Market Expansion For Long-Term Margin Stability

BioCon: To Acquire CCDS Of BioCon Biologics For 3 Billion Rupees 💰📈

BIOCON: Q2 CONS NET PROFIT 1.3B RUPEES VS 271M (YOY); EST 750M -- Q2 REVENUE 42.95B RUPEES VS 35.9B (YOY); EST 41.5B (CORRECTION IN REVENUE)

BIOCON: Q2 EBITDA 8.35B RUPEES VS 6.85B (YOY); EST 8.40B -- Q2 EBITDA MARGIN 19.45% VS 19.09% (YOY); EST 21%

BIOCON: Q2 CONS NET PROFIT 1.3B RUPEES VS 271M (YOY); EST 750M -- Q2 REVENUE 45.95B RUPEES VS 35.9B (YOY); EST 41.5B

JB CHEMICALS & PHARMA: Q2 CONS NET PROFIT 2.08B RUPEES VS 1.75B (YOY) -- Q2 REVENUE 10.85B RUPEES VS 10B (YOY) -- Q2 EBITDA 3.1B RUPEES VS 2.7B (YOY) -- Q2 EBITDA MARGIN 28.54% VS 27.04% (YOY)

Zydus Lifesciences: Company Gets First Approval From Chinas NMPA For Venlafaxine Extended-Release Capsules, 75mg And 150mg; Capsules For Major Depressive Disorder And Anxiety Disorders

Divis: Company Reports 59% Monthly Drop and 38% Yearly Decline in Exports Measured in Dollar Value

Alkem Labs: EU GMP Inspection at Baddi Facility Ends Without Major Issues 🚦✅

Glenmark Pharma: Co Secures China Approval For RYALTRIS®, Reinforcing Respiratory Innovation Leadership

DR. REDDYS LABORATORIES LTD.: RS. 128.07 CRORES NSE BLOCK TRADE; FOR ~ 1,068,662 SHARES, AT RS. 1198.40

Lupin: Plans To Release Risperdal Consta Soon And Recently Introduced A Generic Version Of Ravicti - Concall Update

Lupin: Company Aims to Introduce 80+ New Products in India Soon, Starting with Semaglutide Launches - Concall Update

Lupin: Full Year FY26 Tax Rate Anticipated Between 21-22% 💰 -- Company Aims for 5 Biosimilar Products in Market by FY30, Expects to Outperform IPM by 1.2X to 1.3X for India Formulations Business - Concalls Update

Lupin: Full Year FY26 EBITDA Margins Projected at 25-26%, Up from Previous Estimate of 24-25% -- FY27 EBITDA Margins Expected to Stay at 24-25% - Conference Call Update

Divis Laboratories: Citi maintains buy on Divis Laboratories, hikes target price to Rs 9,140 from Rs 7,750

Divis Labs: HSBC on Divis Labs Buy, target price Rs 7400

Divis Labs: GS on Divis Labs Neutral, target price Rs 6765

Torrent Pharma: Jefferies on Torrent Pharma Buy, target price Rs 4300

Torrent Pharma: Company Avoids Giving Guidance For Germanys Performance Because Of Ongoing Supplier Problems. Company Shows Margin Growth, With Operating EBITDA Rising By 15% While Revenue Increased By 14% - Concall Update

Torrent Pharma: Aims To Submit 4-5 ANDAs This Fiscal Year, Increasing To About 10 Next Year And 15 The Year After - Concall Update

Lupin: Lupin Bioresearch Center Receives Zero Observations from U.S. FDA After Successful Inspection and Assessment

Torrent Pharmaceuticals: Co Projects Robust Growth Across India, U.S., And Emerging Markets With 14% Consolidated Revenue Rise To ₹3,302Cr; Expanding Chronic And Specialty Portfolio; Aims To Strengthen U.S. Pipeline With 50+ ANDA Filings And New Manufacturing Facilities; Focused On Margin Improvement Through Cost Rationalization And Product Mix Optimization

Piramal Finance: Co Focuses On Scaling Retail Loan Book Beyond ₹60,000Cr With 35% YoY Growth; Sharpening Focus On MSME, Housing, And Digital Lending Segments; Aims To Reduce Wholesale Portfolio To 25% Of Assets By Fy27; Expanding Through “Phygital” Hubs, Enhanced Analytics, And Cross-Sell Opportunities; Targeting Stable Margins And Sustainable RoE Recovery

Zydus Lifesciences: Gets Tentative Approval From USFDA For Olaparib Tablets In 100 MG And 150 MG Dosages

TORRENT PHARMACEUTICALS: Q2 EBITDA 10.8B RUPEES VS 9.4B (YOY) -- Q2 EBITDA MARGIN 32.80% VS 32.5% (YOY)

TORRENT PHARMACEUTICALS: Q2 CONS NET PROFIT 5.9B RUPEES VS 4.53B (YOY) -- Q2 REVENUE 33B RUPEES VS 28.9B (YOY)

DIVIS LAB: Q2 REVENUE 27.1B RUPEES VS 23.3B (YOY)

DIVIS LAB: Q2 EBITDA 8.9B RUPEES VS 7.2B (YOY); EST 8.1B -- Q2 EBITDA MARGIN 32.7% VS 30.6% (YOY); EST 32%

DIVIS LABORATORIES: Q2 CONS NET PROFIT 7B RUPEES VS 5.1B (YOY); 6B EST

Cipla: Mounjaro Becomes India’s Top-Selling Drug By Revenue In October, With Monthly Sales Of ₹1 Billion; Eli Lilly Partners With Cipla For Its Distribution In India

Zydus Lifesciences: Guidance - Co Maintains Guidance Of 26%+ Ebitda Margin For The Full Year, Despite Lower Margins From Recent Acquisitions Like Comfort Click -- Co Expect To Launch 25+ Products In The Us Market This Fiscal Year- Concall Update

Zydus Lifesciences: Guidance - Management Expects To Achieve Their Targeted Top-line Growth And Profitability For Fy26- Concall Update

Piramal Pharma: Maintains Long-Term Revenue Goal Of $2 Billion With 25% EBITDA Margins, Plans To Spend $100-120 Million On Capital Expenditures For FY26 After Spending $49 Million So Far.

Piramal Pharma: Reduces FY26 Revenue Growth Forecast To Flat With Low-Teens EBITDA Margins, Expects Stronger Revenue And EBITDA Performance In H2 FY26 Compared To H1

Aurobindo Pharma: Expects Ongoing Growth Due To Multiple Factors Such As Pen-G Facility Ramp-Up, Biosimilar Portfolio Launch, Biologic CMO Progress, Injectable Business Enhancement, Supply From China Plant To Europe, New Product Releases, And Acquisition Of Lannett In The U.S

Aurobindo Pharma: China Plant Aiming For EBITDA Breakeven By Q3-Q4 FY 26, According To Concall Update.

Aurobindo Pharma: Company Expects EBITDA Margins of 20-21% for FY 26 and Anticipates Over €1 Billion in Revenue for Europe by FY 26 - Concall Update

Lupin: Co Targets Mid-Teens Growth Led By U.S. Generic Launches, India Branded Portfolio, And Biosimilar Expansion; Strengthening Respiratory And Cardiovascular Segments; Expects Margin Expansion From Cost Efficiency, Complex Product Mix, And Increased API Backward Integration; R&D Focus On Peptide And Inhalation Therapies

Mankind Pharma: Co Guides For Sustained 20 % + Revenue Growth, Led By Chronic Therapy And Bsv Specialty Portfolio Expansion, With Strong Export Ramp-Up (+82 % YoY). Expects Margin Tailwinds From Specialty And Super-Specialty Products, Alongside Revival In Consumer Healthcare. Aims To Strengthen Otc Leadership And Double Export Contribution Over Next 3 Years

MANKIND PHARMA: Q2 CONS NET PROFIT 5.11B RUPEES VS 6.56B (YOY) -- Q2 REVENUE 36.97B RUPEES VS 30.61B (YOY) -- Q2 EBITDA 9.21B RUPEES VS 8.47B (YOY) -- Q2 EBITDA MARGIN 24.92% VS 27.67% (YOY)

Zydus Lifesciences: Company Announces 13.5% Growth In US Formulations Business, As Compared To Full Year Growth In Single Digits In US Business

Zydus Lifesciences: Company Announces 13.5% Growth In US Formulations Business, As Compared To Full Year Growth In Single Digits In US Business

Zydus Lifesciences: Board Supports Fundraising Plan Of Up To ₹5,000 Crores Via Different Securities, Waiting For Shareholder And Regulatory Approvals

ZYDUS LIFESCIENCES: Q2 REVENUE 61B RUPEES VS 52.4B (YOY)

ZYDUS LIFESCIENCES: Q2 EBITDA 20.15B RUPEES VS 14.6B (YOY) -- Q2 EBITDA MARGIN 32.92% VS 27.91% (YOY)

ZYDUS LIFESCIENCES: Q2 CONS NET PROFIT 12.6B RUPEES VS 9.1B (YOY)

Piramal Pharma: Co Expects Flat Revenue Growth This Year With Moderating EBITDA Margins 📉💼 --Concall Updates

Zydus Lifesciences: Gets USFDA Orphan Drug Status For Desidustat To Treat Beta-Thalassemia; Can Enjoy Seven-Year Marketing Exclusivity After Approval

Aurobindo Pharma: Plans To Increase Production At Kakinada Pen-G Plant - Concall Update

Aurobindo Pharma: Reports Low Revlimid Sales In Q2 And Anticipates No Sales In Q3 - Concall update

Aurobindo Pharma: Predicts Break-Even for China Plant in Third or Fourth Quarter - Concall Update

Aurobindo Pharma: Reports Low Revlimid Sales In Q2 And Anticipates No Sales In Q3

Aurobindo Pharma: Indicates No Major Capital Expenditures Expected Soon.

PIRAMAL PHARMA: Q2 EBITDA 1.58B RUPEES VS 3.4B (YOY) -- Q2 EBITDA MARGIN 7.73% VS 15.25% (YOY)

PIRAMAL PHARMA: Q2 CONS NET LOSS 992M RUPEES VS PROFIT 226M (YOY) -- Q2 REVENUE 20.4B RUPEES VS 22.4B (YOY)

AUROBINDO PHARMA: Q2 EBITDA 16.8B RUPEES VS 15.66B (YOY) -- Q2 EBITDA MARGIN 20.25% VS 20.1% (YOY)

AUROBINDO PHARMA: Q2 CONS NET PROFIT 8.48B RUPEES VS 8.17B (YOY) -- Q2 REVENUE 82.9B RUPEES VS 78B (YOY)

AUROBINDO PHARMA: Q2 EBITDA 16.8B RUPEES VS 15.66B (YOY) -- Q2 EBITDA MARGIN 20.25% VS 20.1% (YOY)

AUROBINDO PHARMA: Q2 CONS NET PROFIT 8.5B RUPEES VS 8.17B (YOY) -- Q2 REVENUE 82.85B RUPEES VS 78B (YOY)

Sun Pharma: Cos Executive Expresses Willingness to Explore Growing Manufacturing Operations in the U.S.

Lupin: Co Receives EIR from U.S. FDA for its Pithampur Unit-3 Facility

SUN PHARMA INDUSTRIES: Q2 cons NET PROFIT 31.18B RUPEES VS 30.4B (YOY) -- Q2 REVENUE 144.78B RUPEES VS 133B (YOY) -- Q2 EBITDA 45.27B RUPEES VS 39.4B (YOY) -- Q2 EBITDA MARGIN 31.27% VS 29.6% (YOY)

Zydus Life: Co Receives EIR For SEZ II Manufacturing Facility, Ahmedabad

Zydus Lifesciences: Receives Tentative USFDA Approval For 4 Mg Budesonide Delayed-Release Capsules For Mild To Moderate Active Crohns Disease; Total Approvals Now At 425

Glenmark Pharmaceuticals: Plans To Release 8.4% Sodium Bicarbonate Injection USP In November 2025, Which Is Bioequivalent To Abbotts Benchmark Drug; The Market Currently Shows Annual Sales Around $63.8 Million.

Ajanta Pharma: Jefferies maintains Buy on Ajanta Pharma with Price Target of Rs 3120

Gland Pharma: Expects Improved Growth In The Second Half Due To New Product Launches And Cenexis Recovery. 📈💊

Wockhardt: Companys Domestic Biotech Business Grows Strongly and Is Expected to Continue Thriving in the Future. 🚀💊

Gland pharma: Co projects mid-to-high single-digit revenue growth through complex injectables, biosimilars, and cdmo scaling; expanding manufacturing in India and broadening global launches across the u.s., europe, and emerging markets

Zydus Lifesciences: Board Meeting Scheduled For November 6 To Discuss Fundraising Up To 50 Billion Rupees

Gland Pharma: Company Plans to Boost GLP-1/Cartridge Production Capacity from 40 Million to 140 Million Units

GLAND PHARMA: Q2 CONS NET PROFIT 1.84B RUPEES VS 1.64B (YOY) -- Q2 REVENUE 14.87B RUPEES VS 14.06B (YOY) -- Q2 EBITDA 3.14B RUPEES VS 2.97B (YOY) -- Q2 EBITDA MARGIN 21.11% VS 21.13% (YOY)

Cipla: Co To Purchase Full Stake In Inzpera Healthsciences Limited For Approximately INR 110.65 Crores; Inzpera Focuses On Pediatric Pharmaceutical And Wellness Products

WOCKHARDT: Q2 REVENUE 7.82B RUPEES VS 8.1B (YOY)

WOCKHARDT: Q2 EBITDA 1.78B RUPEES VS 1.28B (YOY) -- Q2 EBITDA MARGIN 22.76% VS 13.60% (YOY)

WOCKHARDT: Q2 CONS NET PROFIT 780M RUPEES VS LOSS 220M (YOY)

Ajanta Pharma: Announces First Interim Dividend Of Rs. 28 💰📈

AJANTA PHARMA: Q2 EBITDA 3.3B RUPEES VS 3.1B (YOY) -- Q2 EBITDA MARGIN 24.22% VS 26.22% (YOY)

AJANTA PHARMA: Q2 REVENUE 13.5B RUPEES VS 11.9B (YOY)

AJANTA PHARMA: Q2 CONS NET PROFIT 2.6B RUPEES VS 2.16B (YOY)

Alkem Laboratories: Company Reveals Partnership With IIT Bombay To Set Up A Research Centre For Immuno-Therapeutics And Regenerative Medicines; Alkem Foundation To Support 20-25% Of CSR Commitments Over Seven Years.

Biocon: Co Subsidiary Changes Name And Status To Public Company Effective October 29, 2025. 📈🏢

Cipla: Cos CEO Vohra States Eli Lilly Has Sufficient Supply of Mounjaro. 💊🔍

Lupin: Introduces Vitalyfe™, An AI-Driven Cardiometabolic Wellness Platform To Support Indias Workforce In Regaining Heart Health And Incorporating Wellness In Health Benefits. 💪🩺

Cipla: Umang Vohra Will Leave His Position As MD & GCEO On March 31, 2026; Achin Gupta Will Take Over From April 1, 2026; Ms. Meera Vanjari Is Appointed Global General Counsel Starting April 1, 2026. 📅👔

Cipla: Plans To Introduce 4 Main Respiratory Products By 2026, Including Gadvair In Fourth Quarter Of FY26, And 3 Peptide Products, Like Liraglutide. 💉📅

CIPLA: Q2 EBITDA 18.94B RUPEES VS 18.9B (YOY); EST 18.82B -- Q2 EBITDA MARGIN 24.97% VS 26.7% (YOY); EST 25.5%

CIPLA: Q2 CONS NET PROFIT RUPEES 13.5B VS 13B (YOY); EST 13.48B

Dr Reddy: CITI on DR Reddys Sell, TP Rs 990

Dr Reddy: Jefferies maintains underperform on Dr Reddys; Target Price Rs. 1,130

Dr Reddy: Morgan Stanley maintains equal-weight on Dr Reddys; Target Price Rs. 1,389

Dr Reddy: BofA maintains buy on Dr Reddy with a target price of Rs 1,600

Zydus Lifesciences: Company Gets Approval From USFDA For Baddi Manufacturing Plant, Being Labeled As Voluntary Action Indicated. 🏭✅

Dr Reddys: Receives Notice For Not Complying With Canadian Regulations On Semaglutide 🇨🇦📉

Zydus Life: To Review Q2 Financial Performance On November 6 📅💼

Lupin: Company Opens New Corporate Offices in New Jersey, Increases Presence in the State, Aids U.S. Healthcare System, and Aims to Hire Over 300 Employees. 🏢🇺🇸

Dr. Reddys Lab: Aiming For Semaglutide Approvals In 87 Nations Within 12-15 Months 📈🌍

Dr. Reddys Labs: Plans To Achieve Target Margins Within Two Years, Depending On The Success Of Important Products Like Semaglutide And Abatacept - Concall Update 📈💊

Dr. Reddys Labs: Expects Gross Margins Between 20-25% In Pharmaceutical Services And Active Ingredients. The Company Aims To Achieve 25% EBITDA Margins By FY27 Despite Short-Term Challenges From Lenalidomide Decrease. 📊💊

Dr. Reddys Labs: Anticipates SG&A Costs Will Be 28-30% Of Sales, While R&D Expenses Are Projected To Stay Around 7% Of Sales - Conference Call Update 📊💼

Dr. Reddys: Macquarie on DR Reddys Neutral, TP Rs 1190

Zydus Life: Company Unit Zydus Medtech France SAS Completes Acquisition Of Remaining 14.4% Stake In Amplitude Surgical SA, Making It A Fully Owned Subsidiary. 🇫🇷🔗

Dr. Reddys: Co Projects Ongoing Growth Through Biosimilars, API Pipeline, Global Expansion, and 22% ROCE - Strong Cash Flow With Europe/Emerging Markets Growth and High-Margin Products Expected to Boost Long-Term Profits. 🌍💰

Zydus Lifesciences: Gets Canada Health Nod For Mesalamine Suppositories Made In Ahmedabad, India. 🇨🇦💊

Dr Reddys Lab: Executive States No Plans For Partnership With Eli Lilly To Launch Tirzepatide In India. 💊🚫

Dr. Reddys Lab: Appoints Sanjay Sharma As CHRO Starting December 1, 2025. 🏥📅

Laurus Labs: Company Promises Improved EBITDA Margins for FY27 Compared to FY26 📈💼

Ajanta Pharma: Board To Discuss First Interim Dividend For FY 2026, Record Date Is Nov 10, 2025 If Approved. 📅

Lupin: Introduces Authorized Generic Version Of Ravicti® Oral Liquid In The U.S. For Chronic Urea Cycle Disorders Management. 💊🇺🇸

Laurus Labs: Expects Better EBITDA Margins Through Focus on Small and Large Molecule CDMO and Improved Asset Utilization 📈💪

Laurus Labs: Expects Gross Margins To Stay Near 60%, Improving From Earlier Forecasts Of 55% And 50%, Due To Business Growth And Stronger Positions In ARV And Oncology. 📈💊

Laurus Labs: Plans $600 Million Investment For New 530-Acre Complex Over 8 Years, Not Linked To Current Facilities. Company Expects Gross Margins To Stay About 60% And Aims To Increase Asset Turnover From 0.9 To 1.1 - Concall Update 📈🏗️

Laurus Labs: Forecasts Antiretroviral Sales Around ₹2,500 Crore With A Margin Of ₹200 Crore And Plans To Invest ₹1,000 Crore In Capital Expenditure For FY26. 📊💰

Laurus Labs: Jefferies on Laurus Labs U-P, TP raised to Rs 700

Biocon: Biocon Biologics Gets Approval from Health Canada for Yesintelik™ and Yesintelik™ I.V. (Ustekinumab), A Biosimilar to Stelara®. 🇨🇦💉

Cipla: Company Partners With Eli Lilly To Market New Tirzepatide Brand Named Yurpeak® In India, Aiming To Improve Access For Type 2 Diabetes And Obesity Treatments. 💊🤝

Laurus Labs: Invests In Manufacturing Network Expansion To Enhance Growth With Capital Expenditure At 15% Of Sales. 📈

Laurus Labs: Co CFO Reports Big Drop In Net Debt Leverage To 1.3X EBITDA Over The Past Year While Continuing To Invest In CAPEX. 📉💼

Laurus Labs: Reports Over 85% Growth In Capital Expenditure For API And CDMO Portfolio Backed By Integrated Drug Product Strategy. 📈

LAURUS LABS: Q2 CONS NET PROFIT 1.95B RUPEES VS 198M (YOY) -- Q2 REVENUE 16.5B RUPEES VS 12.24B (YOY)

LAURUS LABS: Q2 EBITDA 4B RUPEES VS 1.79B (YOY) -- Q2 EBITDA MARGIN 24.39% VS 14.57% (YOY)

Sun Pharmaceutical Industries Ltd.: Rs. 21.42 Crores NSE Block Trade; for ~ 125,307 Shares, at Rs. 1709.50

Aurobindo Pharma: Co Creates Fully Owned Subsidiary Aurobindo Pharma Chile SpA With Initial Share Capital of CLP 1,000,000; No Regulatory Approvals Needed 🇨🇱💼

Glenmark Pharmaceuticals: Co Will Introduce Ropivacaine Hydrochloride Injection USP In November 2025, Competing With Naropin®, Which Made About $20.9 Million Annually. 💉

Biocon: Biocon Biologics Gets Health Canada Approval For Yesintek And Yesintek I.V. (Ustekinumab), A Biosimilar Of Stelara. 🇨🇦💊

Sun Pharma: Co Appoints Jeremy Allen As New Vice President Of Corporate Affairs For North America. 🌎✨

Lupin: Company Will Review Q2 Earnings On November 6 📅💰

J.B. Chemicals & Pharmaceuticals :CCI Greenlights Torrent Pharmas Takeover of Co With Adjustments. 🏥✅

Dr. Reddys Laboratories: Co Receives USFDA’s Establishment Inspection Report for Srikakulam Facility; Inspection Closed with Voluntary Action Indicated Status

Piramal pharma: Co says believe ppl is well-poised to benefit from crdmo demand tailwinds and bake in a robust ~19% crdmo sales cagr over fy2026-28e

Divis Lab: Trump Promises Lower Ozempic Prices in the U.S., Currently at $1300, While Its Only $130 in London. 💊💰

Divis Lab: Faces Negative Impact As Trump Plans 90% Price Cut For Weight Loss Drugs 📉💊-RTRS

IPCA Laboratories: Co Board Agrees to Sell Drug Intermediates and API Manufacturing Unit to Suleshvari Pharma for ₹22.15 Crore 💊💰

BICON: Company Expands Collaboration With Civica To Introduce Private-Label Insulin Glargine In The U.S.; Aims To Boost Supply Of Affordable Insulin For 38.4 Million Diabetes Sufferers. 💉🤝

Dr Reddys Laboratories: Acquires Biopharmaceutical Firm To Broaden Product Range 🚀💊

Ipca Laboratories: Establishes New Subsidiary "Ipca Pharmaceuticals GmbH" In Germany With Initial Capital Of €25,000 To Manage Product Registrations And Distribute Generic Drugs. 🇩🇪💊

ALKEM LABORATORIES LTD.: RS. 56.15 CRORES NSE BLOCK TRADE; FOR ~ 100,805 SHARES, AT RS. 5570.00

Torrent Pharma: Aims To Raise ₹14,000 Crore Through Bond Sale For JB Chemicals Purchase. 💰📈- ET

LAURUS LABS: CO REPORTS GROWTH OF 65% FOR SEPT QUARTER -- CO REPORTED GROWTH OF 52% FOR THE MONTH OF SEPT

Biocon Ltd.: Rs. 22.49 Crores NSE Block Trade; for ~ 642,850 Shares, at Rs. 349.80

Lupin: Company Will Share Phase 1 Data On LNP3693 At ESMO Congress 2025, Discussing Safety And Anti-Tumor Effects On October 19, 2025. 🩺📅

Mankind Pharma: Co executes ₹797 crore Business Transfer Agreement with wholly owned subsidiary Bharat Serums & Vaccines for acquisition of Women’s Health Rx branded generics portfolio

Lupin Limited: Starts Partnership Program To Grow PrecisionSphere™ Long-Acting Injectable Platform; Aims To Create Collaborations For Longer Product Lifecycles; First Product Gets US FDA Approval. 💉🤝

Laurus Labs: To Review Second Quarter Results On October 23 📊🗓️

Torrent Pharma: CCI Raises Concerns Over JB Chemicals And Torrent Pharma Agreement. ⚖️💼-ZEE

Lupin: Citi maintains Buy on Lupin with Price Target of Rs 2260

Sun Pharma: NCLT Approves Merging Of Sun Pharmaceutical Medicare And Other Units With Co🚀⚖️

Lupin: Company Plans $250M Pharmaceutical Plant In Coral Springs To Create 200 New Jobs By 2030, Focused On Producing 25 Important Respiratory Medicines. 💊🏭

Aurobindo Pharma: Cos Hyderabad Unit Faces US FDA Concerns, Similar To Lupins Pithampur Unit With 8-10% Revenue Share And 22 Major Filings - CNBC TV18🏥📉

Biocon: Company’s Unit Biocon Pharma and Carnegie Pharmaceuticals Get USFDA Tentative Approval for Rifaximin Tablets (550 mg) 📈💊

Zydus Lifesciences: Co receives approval from Health Canada for Liothyronine tablets 5 mcg and 25 mcg

Zydus Lifesciences: Gets USFDA Final Approval For Deflazacort Oral Suspension 22.75 MG/ML, Production Will Happen In Doppel, Italy; The Group Now Holds 424 Approvals And Has Filed 487 ANDAs Since FY 2003-04. 🏥💊

Lupin: US FDA Labels Pithampur Unit-2 Inspection As Official Action Indicated With Four Observations Documented In Form-483. 🏭📋

Lupin: Company Launches Liraglutide Injection In The U.S. With Estimated Annual Sales Of $350 Million. 💉💰

Biocon: Company Gets Approval for Early Redemption of ₹1,070 Crore Unlisted Secured NCDs. 💰✅

Zydus Lifesciences: USFDA Sends Complete Response Letter To :Co For Sentynl Therapeutics CUTX-101 NDA; No Issues With Efficacy Or Safety 📨🔍

Lupin: Company Introduces Rivaroxaban Oral Suspension, 1 MG/ML In The U.S.; Equivalent To Xarelto®; Projected Yearly Sales Of USD 11 Million. 💊🇺🇸

Biocon: Biocon Biologics Gets U.S. Approval Date for Bosaya™ and Aukelso™, Denosumab Biosimilars. 🇺🇸💊

Wockhardt: Company Files New Drug Application With U.S. FDA For Zidebactam-Cefepime To Treat Serious Gram-Negative Infections 🏥💊

Sun Pharma: Citi maintains buy on SunPharma; Target Price Rs 2,180

Lupin: Co receives U.S. FDA approval for Rivaroxaban oral suspension, 1 mg/mL

Zydus Lifesciences: Co extends closing date for acquisition of Sterling Biotech’s API business to December 31, 2025

Lupin: MorganStanley maintains Equal-weight on Lupin with Price Target of Rs 2096

Lupin: Company Expands Global Specialty Ophthalmology Sector by Acquiring Visufarma from GHO Capital. 👁️💼

Zydus Lifesciences: Tax Authorities Withdraw Demand Of 358.97 Million Rupees Against Co 💰📉

Wockhardt: “Wockhardt’s Miqnaf® Phase 3 Study Published in The Lancet, Marking Milestone for India’s Antibiotic Innovation”

CIPLA LTD.: RS. 51.05 CRORES NSE BLOCK TRADE; FOR ~ 331,705 SHARES, AT RS. 1539.10

Torrent Pharma: Issues Commercial Papers Worth 2 Billion Rupees 💰📈

Lupin: Co Receives Tentative U.S. FDA Approval for Bictegravir, Emtricitabine, and Tenofovir Alafenamide Tablets

Cipla: Co Board Meeting On Oct 30 To Consider Q2 Results

Ipca Laboratories: Co to Transfer Monoclonal Antibody Biosimilar Technology to Puerto Rico’s BioScience Hub

Glenmark Pharma: Co Inks $1.1B Deal With Hengrui For Exclusive Rights To HER2-Targeting Cancer Therapy Across Multiple Regions

Lupin: DGTR Starts Investigation Into Anti-Dumping of Ethambutol Hydrochloride Imports From China and Thailand. 📈🔍

Torrent Pharma: South Africas Competition Commission Approves Cos Stake Acquisition In J. B. Chemicals. 📈🤝

Alkem Laboratories: Co receives GST appeal order for Rs. 35.11 crore demand plus Rs. 3.51 crore penalty, plans to contest the order

Dr. Reddys: Gets Good CHMP Opinion From European Medicines Agency For AVT03 (Denosumab), A Planned Biosimilar To Prolia® And XGEVA®. 💊👍

Alkem Lab: Co launches Pertuza, a pertuzumab biosimilar, in India for treatment of HER2-positive breast cancer

Dr. Reddys Lab: To Review Q2 Results On October 24 📊🗓️

Sun Pharma: Macquarie on Sun Pharma O-P, TP Rs 2000

Zydus Life: Company Gets EIR From USFDA For Oncology Injectable Facility In SEZ1, Ahmedabad After Inspection From June 9–18. 🏭

Lupin: U.S. FDA completes pre-approval inspection at Cos Pune Biotech facility, noting four observations

Aurobindo Pharma: Small Fire Occurs At APL Healthcare Limited Unit-IV Due To Electrical Short Circuit; No Casualties Reported; Temporary Production Affected By About 3% Of Monthly Capacity; Refurbishment To Be Finished In A Few Weeks. 🔥🏥

Aurobindo Pharma: Cura Teq Biologics Finishes Phase 3 Study For Denosumab Biosimilar; Study Achieved All Goals With No Major Differences From Prolia; Filings For Approval Expected In EU And US By January 2026. 🧪📅

Dr. Reddy’s: Co Promoters Transfer 20.58% Stake via Off-Market Deal to Family Trusts for Succession Planning

Biocon: Biocon Biologics’ Yesafili® (aflibercept) Added To Ontario’s Public Drug Formulary, Ensuring Funded Access For Patients With Retinal Diseases In Canada

Glenmark Pharma: Astria Therapeutics Shares Positive Initial Outcomes from Phase 1A Trial of STAR 0310 - CNBC TV18📈🧪

Glenmark Pharma: Signs Deal With Astria For Developing Monoclonal Antibodies - CNBC TV18 🤝💉

Sun Pharma: Citi maintains buy on Sun Pharma with Price Target of Rs 2180

Laurus Labs: GoldmanSachs maintains sell on Laurus Labs with Price Target of Rs 675

Torrent Pharma: Company Releases 2 Billion Rupees in Commercial Papers 💵📄

Aurobindo Pharma: Co Incorporates Wholly Owned Subsidiary in Malaysia to Expand Pharmaceutical Business

Biocon: Co Biologics Secures U.S. FDA Approval for Bosaya™ and Aukelso™, Denosumab Biosimilars to Prolia® and Xgeva®, with Provisional Interchangeability Designation

Lupin: Gets FDA Approval For Lenalidomide Capsules, Which Are Equivalent To Revlimid®. Expected Annual Sales In The U.S. At $7.51 Billion. 💊🇺🇸

Lupin: Co Receives Six Observations from U.S. FDA After Inspection of Nagpur Injectable Facility

Dr. Reddy’s: Cos Launches Novel Molecule Tegoprazan in India Under Brand Name PCAB

Torrent Pharma: Indian Patent Office Cancels Novartis Cardiac Drug Patent for Vymada (Entresto), Allowing Generics to Enter Market. 💊⚖️ -ET

Laurus Lab: Company Reports 94% Export Growth in August 📈

Zydus Lifesciences: ZyVet Animal Health Introduces First FDA-Approved Generic Medications for Dog Urinary Incontinence and Long-Term Heart Care for Pets. 🐾💊

Glenmark Pharma: Co Executes Business Transfer Agreement to Transfer Consumer Care Business to Wholly Owned Subsidiary

Sun Pharmaceutical Industries Ltd.: Rs. 48.79 Crores NSE Block Trade; for ~ 303,092 Shares, at Rs. 1609.80

DIVIS LABORATORIES LTD.: RS. 62.27 CRORES NSE BLOCK TRADE; FOR ~ 103,332 SHARES, AT RS. 6026.00

Dr. Reddy’s Labs: Co. Buys Stugeron® Portfolio Worth USD 50.5M From Johnson & Johnsons Partner To Enhance CNS And Anti-Vertigo Division In 18 Markets. 💊🌍

Biocon: Company Opens Its First Manufacturing Plant In Cranbury, New Jersey, USA 🇺🇸🏭

Lupin: Company Gets U.S. FDA Approval For Risperidone Long-Acting Injectable With 180-Day CGT Exclusivity, First Product From Its Nanomis Long-Acting Injectable Platform. 💉🇺🇸

Torrent Pharma: to Acquire 26% Stake in Torrent Urja 27 Pvt Ltd for Captive Hybrid (Solar + Wind) Power Project in Gujarat

DIVIS LABORATORIES LTD.: RS. 51.91 CRORES NSE BLOCK TRADE; FOR ~ 87,739 SHARES, AT RS. 5916.50

Sun Pharma: US FDA Inspects Halol Facility, Classifying It As Official Action Indicated And Subjecting It To Import Alert, Resulting In Refused Shipments To The US. 🏥🚫

Gland Pharma Ltd.: Rs. 45.99 Crores NSE Block Trade; for ~ 240,922 Shares, at Rs. 1909.00

Glenmark Pharma: Cos Unit IGI Secures $700 Million Upfront Payment From AbbVie for Licensing Agreement for ISB 2001. 💰💊

Sun Pharma: Stops Making Vecuronium Bromide Injection 20 MG, According To FDA. 💉🚫

Zydus Lifesciences: Co’ Jarod Injectable Plant Inspection by USFDA Concludes with 4 Observations; No Data Integrity Issues Found

Aurobindo Pharma: US FDA Finishes Inspection Of The Company’s Unit-XII With Eight Procedural Observations; No Financial Or Operational Effects Noted. 🏥🔍

Sun Pharmaceutical Industries Ltd.: Rs. 40.62 Crores NSE Block Trade; for ~ 255,995 Shares, at Rs. 1586.70

Sun Pharmaceutical Industries Ltd.: Rs. 32.31 Crores NSE Block Trade; for ~ 203,417 Shares, at Rs. 1588.20

Glenmark Pharmaceuticals: Starts Phase 3 Clinical Trial For Envafolimab In Stage III Non-Small Cell Lung Cancer; Approval From DCGI Given For Enrollment In India; Applications Submitted For Trials In Russia, Brazil, And Mexico. 🧪🌍

Biocon: USFDA Finishes Inspection At :Biocon Biologics Facility In India, Issuing Form 483 With Five Observations. These Observations Are Based On Procedures And Do Not Relate To Data Integrity, Systemic Non-Compliance, Or Quality Oversight. 🔍🧪

Zydus Lifesciences: Co and Synthon Sign Exclusive Licensing & Supply Agreement for Generic Ozanimod Capsules in U.S. Market

Lupin: Gets U.S. FDA Approval For Risperidone Long-Acting Injectable Suspension; First Product From Nanomis LAI Platform; 180-Day CGT Exclusivity; Estimated Annual Sales Of USD 190 Million In The U.S. 💉💰

MANKIND PHARMA LTD.: RS. 51.37 CRORES NSE BLOCK TRADE; FOR ~ 200,287 SHARES, AT RS. 2564.60

Glenmark Pharma: Cancer Medications May Get GST Exemption 💊🩺 -BS

Dr Reddys Laboratories: Cancer Medications Might Be Excluded From GST. 💊🚫

Gland Pharma: Cancer Medications Might Be Excluded From GST. 💊🚫 -BS

Zydus Lifesciences: Cancer Medications Could Be Free From GST. 💊💰 -BS

Zydus Lifesciences: Company Introduces Vaxiflut, Indias First Trivalent Influenza Vaccine For Flu Protection. 💉🇮🇳

Glenmark Pharma: U.S. Ready to Introduce Eribulin Mesylate Injection in Single-Dose Vials 💉🇺🇸

SUN PHARMACEUTICAL INDUSTRIES LTD.: RS. 980.02 CRORES NSE BLOCK TRADE; FOR ~ 6,227,856 SHARES, AT RS. 1573.60

Aurobindo Pharma: Company Confirms US FDA Inspection Completion at Wholly Owned Subsidiarys Unit-I, Received Form 483 With 5 Procedural Observations and No Data Integrity Concerns. 🏥📄

Zydus Lifesciences: Co Announces Good Results From Epic-III Phase 2(B)/3 Trial Of Saroglitazar Magnesium For Primary Biliary Cholangitis; Trial Achieved 48.5% Biochemical Response Rate; Regulatory Submission Planned For Q1 2026. 📈💊

Biocon Pharma: Co Receives Tentative U.S. FDA Approval for ANDA of Sitagliptin Tablets (25 mg, 50 mg, 100 mg) to Treat Type 2 Diabetes

Cipla: Co Completes Acquisition of 20% Stake in iCaltech Innovations Pvt. Ltd.

Dr. Reddy’s: Co Gets Interim Stay from Telangana High Court on Income Tax Reassessment Proceedings Related to DRHL Merger

Gland Pharma: Company Gets Green Light For Vasopressin In 5% Dextrose Injection With A Market Size Of $45 Million 💉🚀

Aurobindo Pharma: Companys Unit Gets Approval For Biosimilar Dazubllys From UK’s MHRA. 🏥✅

Divis Labs: CITI on Divis Labs Buy, TP Rs 7750

Piramal Pharma: Company and NewAmsterdam Pharma Invest to Improve Oral Solid Dosage Abilities, Creating Over 20 New Jobs at Sellersville Site. 🏥💼

Lupin: Company Introduces Glucagon For Injection USP, 1mg/Vial In The U.S. With Estimated Annual Sales Of $122 Million 💉🇺🇸

Zydus Lifesciences: Co Gets Final USFDA Approval For Diltiazem Hydrochloride Tablets. 🏥✔️

Zydus Lifesciences: Gets USFDA Final Approval For Prucalopride Tablets, Which Earned USD 186.8 Million In Annual Sales In The US. 💊🇺🇸

DR. REDDY’S: CO RECEIVED USFDA EIR CLASSIFYING ITS MIRYALAGUDA API PLANT INSPECTION AS ‘VAI,’ WITH THE INSPECTION NOW OFFICIALLY CLOSED

Wockhardt: Company Completes Two Pre-NDA Meetings With US FDA And Aims To File New Drug Application By September 2025. 📅💉

WOCKHARDT: Q1 REVENUE 7.4B RUPEES VS 7.39B (YOY)

WOCKHARDT: Q1 EBITDA 720M RUPEES VS 910M (YOY) -- Q1 EBITDA MARGIN 9.8% VS 12.31% (YOY)

WOCKHARDT: Q1 CONS NET LOSS 900M RUPEES VS LOSS 140M (YOY)

Biocon: Company Reports Strong Demand in CRDMO Segment, According to Earnings Call Updates. 📈💬

Biocon: Company Reports Stronger Balance After QIP, Aims For Double-Digit Growth In Generics -Concall Updates 📈💊

Biocon: Company Gets Approval for Deals with Pro-Zeal Green Power, Plans to Acquire 26% Stake in PGPSPL. 🌿🤝

BIOCON: Q1 EBITDA 7.49B RUPEES VS 6.2B (YOY) -- Q1 EBITDA MARGIN 19% VS 18.07% (YOY)

BIOCON: Q1 CONS NET PROFIT 314M RUPEES VS 6.6B (YOY) -- Q1 REVENUE 39.42B RUPEES VS 34.3B (YOY)

Piramal Pharma: Reports Fire At Third-Party Warehouse In Telangana 🔥🔥; Fire Is Under Control And Cause Is Being Investigated; Estimated Inventory Loss Is 450 Million Rupees But Is Insured

Zydus Lifesciences: Co Gets Approval from Health Canada for ZDS-Varenicline Tablets. ✅💊

Lupin: Expects To Reply To The CRL For Dulera In FY26, Aiming For A Possible Launch In The Second Half Of FY27 Or Early FY28. The Company Plans To Introduce Over 80 Products In India In The Next Five Years - Concalls Update. 📅💊

Lupin: Expects At Least High Single-Digit Growth For FY27, Aiming For Ongoing Margin Improvement Through Cost Optimization Efforts. 📈💡

Lupin: Anticipates Strong Double-Digit Growth for Overall Company and U.S. Business in FY26 💹📈. EBITDA Margin Guidance for FY26 Set at 24-25%. Full-Year Effective Tax Rate Expected Around 19%.

Glenmark Pharma: Co USA Unit to Pay $37.75 Million in Antitrust Class Action Settlement, Denies Liability Amid Legal Uncertainty

DIVIS LABORATORIES: Q1 EBITDA 7.29B RUPEES VS 6.2B (YOY) -- Q1 EBITDA MARGIN 30.25% VS 29.37% (YOY)

GLAND PHARMA LTD.: RS. 91.12 CRORES NSE BLOCK TRADE; FOR ~ 455,110 SHARES, AT RS. 2002.20

Aurobindo Pharma: Expects To Surpass €1 Billion In Yearly Revenues For Europe By FY26, Anticipates Strong EBITDA From Q3 Thanks To The PLI Project, And Projects Around ₹150 Crores In PLI Incentives Based On 7,000-8,000 Tonnes Production - Concall Update. 💰📈

Aurobindo Pharma: Keeps EBITDA Margin Outlook At 20-21% For FY26, Anticipates Single-Digit Growth; More Details To Come In November Call. 📈💊

LUPIN: Q1 EBITDA 17.3B RUPEES VS 12.4B (YOY) -- Q1 EBITDA MARGIN 27.56% VS 22.16% (YOY)

LUPIN: Q1 CONS NET PROFIT 12.2B RUPEES VS 8B (YOY) -- Q1 REVENUE 61.6B RUPEES VS 55B (YOY)

Gland Pharma: Cenexi Reaches Breakeven EBITDA This Quarter, Showing The Companys Focus On Cost Management And Efficiency. 📈💰

Gland Pharma: Co Eyes Multi-Year Growth with 3.5x Capacity Expansion in GLP-1 Devices, 20+ RTU Bag Filings, and 15 Co-Developed Product Launches by FY28

GLAND PHARMA: Q1 EBITDA 3.68B RUPEES VS 2.6B (YOY) -- Q1 EBITDA MARGIN 24.42% VS 18.86% (YOY)

GLAND PHARMA: Q1 CONS NET PROFIT 2.2B RUPEES VS 1.44B (YOY) -- Q1 REVENUE 15B RUPEES VS 14B (YOY)

Cipla: USFDA Labels Cos Bommasandra Facility Inspection As Voluntary Action Indicated (VAI) 🏭🔍

Aurobindo Pharma: Companys US Formulations Revenue Slightly Dropped by 1.9% Yearly to INR 3,488 Crore. 📉💊

Aurobindo Pharma: Announces Dividend Of 4 Rupees For Each Share 💰📈

AUROBINDO PHARMA: Q1 EBITDA 16B RUPEES VS 17B (YOY) -- Q1 EBITDA MARGIN 20.37% VS 22.88% (YOY)

AUROBINDO PHARMA: Q1 CONS NET PROFIT 8.2B RUPEES VS 9.2B (YOY) -- Q1 REVENUE 77.9B RUPEES VS 75.7B (YOY)

BIOCON LTD.: RS. 60.87 CRORES NSE BLOCK TRADE; FOR ~ 1,623,691 SHARES, AT RS. 374.90

Mankind Pharma: Management Stays On Track With EBITDA Margin Goals Of 25-26% For FY26 And Gross Margins Above 70% For The Period. The Company Anticipates Dydrogesterone Approvals From Global Markets By The End Of 2025. 📈💊 -Concall Updates

Torrent Pharmaceuticals: USFDA Finishes Inspection At Cos Vizag Facility With No Observations. 🏥✅

Cipla: Company Addresses Report About Pharma Stocks Falling Due to Trumps Letters to 17 Global Drug Companies Requesting Lower Prices, Denies Awareness of the News, States No Undisclosed Information Behind Stock Changes. 📉💊

Sun Pharma: Company States It Was Not Contacted by US President About Drug Pricing and There Are No Related Developments or Legal Actions. 💊🇺🇸

Sun Pharma: Aims to Release Unloxcyt For Advanced Skin Cancer in Second Half of FY 26 Pending FDA Approval 📈💊

Mankind Pharma: Co Sees 1.8x Volume Growth Over IPM in Q1FY26, Led by Anti-Infectives, Respiratory, Cardio and Anti-Diabetics; BSV Integration on Track with Steady Progress and Growth Confidence

MANKIND PHARMA: CO BOARD RECOMMENDED AN INTERIM DIVIDEND OF 1 RUPEE/SHARE

Sun Pharma: Co-Executive States That They Already Have A Strong Presence In The U.S., With No Current Plans To Expand Manufacturing There. 🇺🇸💊

MANKIND PHARMA: Q1 EBITDA 8.47B RUPEES VS 6.71B (YOY) -- Q1 EBITDA MARGIN 23.72% VS 23.42% (YOY)

MANKIND PHARMA: Q1 CONS NET 4.38B PROFIT RUPEES VS 5.32B (YOY) -- Q1 REVENUE 35.7B RUPEES VS 28.67B (YOY)

Mankind Pharma: Co Plans To Raise Short-Term Funds Of Up To 10 Billion Rupees Using Financial Instruments. 💰📈

Mankind Pharma: Co Gets Approval For Buying Womens Health Branded Generic Business. 💊📈

SUN PHARMA INDUSTRIES: COS GLOBAL INNOVATIVE MEDICINES SALES WERE USD 311 MILLION VS EST USD 300M

SUN PHARMA INDUSTRIES: Q1 EBITDA 43B RUPEES VS 36.1B (YOY); EST 36.87B -- Q1 EBITDA MARGIN 31.1% VS 28.51% (YOY); EST 27.5%

SUN PHARMA INDUSTRIES: Q1 REVENUE 138B RUPEES VS 126.5B (YOY); EST 134.2B

SUN PHARMA INDUSTRIES: Q1 CONS NET PROFIT 22.8B RUPEES VS 28.4B (YOY); EST 31.79B

Aurobindo: reciprocal tariffs have exemptions for pharma

JB Pharma: Co Accelerates Sustainable Growth with 30%+ EBITDA Margins, Fastest IPM Expansion Among Top 25, and Multi-Pronged Brand Strategy Targeting Chronic, Ophthalmology, and CDMO Upside

Aurobindo Pharma: To Acquire Full Stake In Lannett Seller Holdco. 💊📈

JB CHEMICALS & PHARMA: Q1 EBITDA 3B RUPEES VS 2.8B (YOY) -- Q1 EBITDA MARGIN 27.50% VS 27.91% (YOY)

JB CHEMICALS & PHARMA: Q1 CONS NET PROFIT 2.02B RUPEES VS 1.77B (YOY) -- Q1 REVENUE 10.9B RUPEES VS 10B (YOY)

Aurobindo Pharma: Agrees To Transfer Shares Of Curateq Biologics. 📈🤝

Dr Reddys Laboratories: Co CFO Expresses Confidence in Double-Digit Sales Growth for FY26, Also Targets 25% EBITDA Margin for FY26 📈💊

Zydus Life: Co Completes Purchase of 85.6% Share in Amplitude Surgical and Plans to File for Simplified Tender Offer. 🏥📈

Torrent Pharma: Faces Growth Issues In Germany Due To Supply Disruption From A Third-Party Manufacturer Expected To Last For A Few More Quarters 📉🇩🇪

Torrent Pharma: Aims for 8-10 New Product Launches Annually in Brazil and 10 Launches in the US This Fiscal Year, Expects Effective Tax Rate of 25-26% for Full Year. 📈💊

Torrent Pharma: Expects At Least 32.9% Adjusted Operating Margin For Q1 FY26 To Stay Steady Throughout The Year -- Company Plans To Hire About 200 More Medical Representatives By Q3, Aiming For 6,900-7,000 Total Representatives By The End Of FY26. 📈💊

Piramal Pharma: Co Charts Bold Course to FY2030: Eyes $2+ Billion Revenue with 25% EBITDA Margin via CDMO Expansion, Consumer Health Growth & Specialty Product Innovation

PIRAMAL PHARMA: Q1 EBITDA 1.07B RUPEES VS 2.04B (YOY) -- Q1 EBITDA MARGIN 5.52% VS 10.48% (YOY)

PIRAMAL PHARMA: Q1 CONS NET LOSS 817M RUPEES VS LOSS 886M (YOY) -- Q1 REVENUE 19.33B RUPEES VS 19.51B (YOY)

Torrent Pharma: Co Eyes Global Scale-Up with Renewed U.S. Strategy, Chronic Leadership in India, and Specialty R&D Focus to Propel Sustainable Growth

Torrent Pharma: Company Issues Non-Convertible Debentures Through Private Placement 📈💰

TORRENT PHARMACEUTICALS: Q1 EBITDA 10.32B RUPEES VS 9.04B (YOY) -- Q1 EBITDA MARGIN 32.47% VS 31.62% (YOY)

TORRENT PHARMACEUTICALS: Q1 CONS NET PROFIT 5.48B RUPEES VS 4.57B (YOY) -- Q1 REVENUE 31.78B RUPEES VS 28.6B (YOY)

AJANTA PHARMA: Q1 REVENUE 13.03B RUPEES VS 11.5B (YOY)

AJANTA PHARMA: Q1 EBITDA 3.5B RUPEES VS 3.3B (YOY) -- Q1 EBITDA MARGIN 27% VS 29% (YOY)

AJANTA PHARMA: Q1 CONS NET PROFIT 2.55B RUPEES VS 2.5B (YOY)

Wockhardt: U.K. Medical Journal Reports Successful Treatment of Severe Drug-Resistant Infection in a U.S. Liver Transplant Patient Using Zaynich. 🏥💊

Laurus Labs: Expects Gross Margins To Stay Between 55-60%, Keeping Net Debt At No More Than 50% Of Annual Revenue And Debt/EBITDA Ratio At 2-2.5X. 📈💼

Laurus Labs: Expects ARV Revenue To Be About Rs 2500 Crore (With A Margin Of Rs 200 Crore) And Anticipates CDMO Contribution To Rise From 30% To Around 50% Of Revenue In The Medium Term. 📈💰

Laurus Lab: Company Gets 531.77 Acres Of Land In Anakapalli District For ₹5,630 Crore Laurus Pharma Zone; Will Create Jobs For 6,350 People In 3 Phases. 🌱🏗️

Dr Reddys Lab: Invests 5.65 Billion Rupees For 45.19% Share In Dr Reddys Russia 🇷🇺💰

LAURUS LABS: Q1 EBITDA 3.82B RUPEES VS 1.71B (YOY); EST 3.24B -- Q1 EBITDA MARGIN 24.35% VS 14.33% (YOY); EST 21.4%

LAURUS LABS: Q1 REVENUE 15.7B RUPEES VS 11.9B (YOY); EST 14.95B

LAURUS LABS: Q1 CONS NET PROFIT 1.63B RUPEES VS 125M (YOY); EST 1.23B

Cipla: Co Plans To Submit Semaglutide For Market Approval Independently And With Partners, Exploring The Economic Viability Of GLP-1 In India - Concall Update💊🤝

Cipla: Co Reports Cash Reserves Of INR 108.38 Billion As Of June 30; Plans To Launch Semaglutide Immediately On Patent Expiry In Major Markets - Concall Update 💰📈

Cipla: Co Discusses Rapid Growth In GLP-1 Market And Is Open To Partnerships While Being Careful With Cash Reserve Usage - Concall Update💰📈

Cipla: Company Gears Up for Gsymbicort and Other Inhaler Launches in FY27 🚀💊

Cipla: Company Plans To Launch 2-3 Peptide Products In FY26. 💊📈

CIPLA: Q1 EBITDA 17.78B RUPEES VS 17.2B (YOY); EST 17.14B -- Q1 EBITDA MARGIN 25.56% VS 25.6% (YOY); EST 24.1%

CIPLA: Q1 REVENUE 69.6B RUPEES VS 67B (YOY); EST 71.06B

CIPLA: Q1 CONS NET PROFIT 13B RUPEES VS 11.8B (YOY); EST 12.07B

Mankind Pharma: Company Establishes Fully Owned Subsidiary In Sri Lanka 🇱🇰✨

Sun Pharma: Co Subsidiaries SPII And Taro Reach $200 Million Antitrust Settlement In U.S., Awaiting Court Approval Without Admission Of Fault. ⚖️💰

Zydus Lifesciences: Co Gets Tentative Approval From USFDA For Ibrutinib Tablets In 140 MG, 280 MG, And 420 MG Strengths, With US Sales At $2.14 Billion. 💊💰

Lupin: Company Gets US FDA Approvals for Liraglutide and Glucagon Injectable Products, With Total US Sales of $572 Million 💉📈

Dr Reddys Labs: Expects PSAI Business To Grow In Double Digits By FY26, While Origin CDMO Aims For USD 100 Million In Sales For FY26 And USD 250-300 Million By 2030 - Concall Update 📈💼

Dr. Reddys Labs: Expects Effective Tax Rate To Be About 25% For FY26, Plans Capital Expenditure Of ₹2500-2700 Crore For FY26, And Anticipates Selling & Administrative Costs To Range From 28-29% Of Total Sales For The Year. 💼💰

Dr. Reddy’s: Co Eyes Volume-driven FY26 Growth With Sustained Margin Leadership, 26+ Product Launches, Robust Global Pipeline, And Deepening Innovation Focus Across CDMO, Biosimilars, And Differentiated Assets

Dr. Reddys Lab: Plans To Introduce Generic Semaglutide In 87 Countries Next Year 🌍💊

Dr Reddy’s Lab: Executive Predicts More Countries Will Adopt Generic Drugs After Patent Expiry. 🌍💊

Dr Reddys Lab: Executive Plans to Release Generic Weight-Loss Medications in 87 Countries Next Year, Targeting Obesity Drugs in Canada, India, Brazil, and Emerging Markets. 🌍💊

DR.REDDYS LABORATORIES: Q1 EBITDA 21.73B RUPEES VS 21.3B (YOY); EST 22.02B-- Q1 EBITDA MARGIN 25.36% VS 27.68% (YOY); EST 25.4%

Dr Reddys: Reports Decrease In North America Revenue Due To Higher Price Erosion In Main Products. 📉💰

DR REDDYS Pricing Challenges for Lenalidomide Anticipated to Increase in U.S. Generic Market 📉💊

DR.REDDYS LABORATORIES: Q1 CONS NET PROFIT 14.18B RUPEES VS 13.9B (YOY); EST 14.78B -- Q1 REVENUE 85.45B RUPEES VS 76.96B (YOY); EST 86.76B